<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CSBJ1916 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEgr5 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 docx ?>
<?FILEmmc2 docx ?>
<?FILEmmc3 xlsx ?>
<?FILEmmc4 xlsx ?>
<?FILEmmc5 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id>
    <journal-title-group>
      <journal-title>Computational and Structural Biotechnology Journal</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2001-0370</issn>
    <publisher>
      <publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9791601</article-id>
    <article-id pub-id-type="pii">S2001-0370(22)00562-1</article-id>
    <article-id pub-id-type="doi">10.1016/j.csbj.2022.12.005</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PCLassoLog: A protein complex-based, group Lasso-logistic model for cancer classification and risk protein complex discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Wang</surname>
          <given-names>Wei</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Yuan</surname>
          <given-names>Haiyan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Han</surname>
          <given-names>Junwei</given-names>
        </name>
        <email>hanjunwei@ems.hrbmu.edu.cn</email>
        <xref rid="af010" ref-type="aff">b</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Liu</surname>
          <given-names>Wei</given-names>
        </name>
        <email>liuwei@hljit.edu.cn</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>a</label>College of Science, Heilongjiang Institute of Technology, Harbin 150050, China</aff>
      <aff id="af010"><label>b</label>College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding authors. <email>hanjunwei@ems.hrbmu.edu.cn</email><email>liuwei@hljit.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>06</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <volume>21</volume>
    <fpage>365</fpage>
    <lpage>377</lpage>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>2</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>3</day>
        <month>12</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Author(s)</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract abstract-type="graphical" id="ab005">
      <title>Graphical abstract</title>
      <fig id="f0030" position="anchor">
        <graphic xlink:href="ga1"/>
      </fig>
    </abstract>
    <abstract id="ab010">
      <p>Risk gene identification has attracted much attention in the past two decades. Since most genes need to be translated into proteins and cooperate with other proteins to form protein complexes to carry out cellular functions, which significantly extends the functional diversity of individual proteins, revealing the molecular mechanism of cancer from a comprehensive perspective needs to shift from identifying individual risk genes toward identifying risk protein complexes. Here, we embed protein complexes into the regularized learning framework and propose a protein complex-based, group Lasso-logistic model (PCLassoLog) to discover risk protein complexes. Experiments on deep proteomic data of two cancer types show that PCLassoLog yields superior predictive performance on independent datasets. More importantly, PCLassoLog identifies risk protein complexes that not only contain individual risk proteins but also incorporate close partners that synergize with them. Furthermore, selection probabilities are calculated and two other protein complex-based models are proposed to complement PCLassoLog in identifying reliable risk protein complexes. Based on PCLassoLog, a pan-cancer analysis is performed to identify risk protein complexes in 12 cancer types. Finally, PCLassoLog is used to discover risk protein complexes associated with gene mutation. We implement all protein complex-based models as an R package PCLassoReg, which may serve as an effective tool to discover risk protein complexes in various contexts.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>Protein complex</kwd>
      <kwd>Deep proteomic data</kwd>
      <kwd>Group Lasso</kwd>
      <kwd>Logistic model</kwd>
      <kwd>Cancer classification</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s0005">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0005">Identifying risk genes is the first step in revealing the molecular mechanism of cancer, finding drug targets, and developing novel therapeutic strategies. Since the advent of high-throughput omics data, a plethora of computational approaches have been developed to identify risk genes <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>. However, since most genes need to be translated into proteins and cooperate with other proteins to form protein complexes or functional modules to carry out cellular functions, although risk genes provide potential targets for cancer research, they are inherently insufficient in revealing the underlying molecular mechanisms and guiding the development of therapeutic strategies from a comprehensive perspective. Protein complexes are key molecular entities that integrate multiple gene products to perform cellular functions <xref rid="b0035" ref-type="bibr">[7]</xref>. They are basic representatives of functional modules. Data from single cell organisms provide evidence that&gt;50 % or even 80 % of proteins work in protein complexes (complexome) <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>. Protein complexes play critical roles in an array of biological processes, including protein synthesis, signaling and cellular degradation processes <xref rid="b0035" ref-type="bibr">[7]</xref>. Given the vital functions of these macromolecular machines, identifying risk protein complexes in tumor samples is fundamental to our understanding of cancer biology. Furthermore, the sophisticated organization of individual proteins into macromolecular assemblies significantly extends the functional diversity of individual proteins and allows cells to acquire novel functionalities that are beyond the performance of individual proteins <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. Thus, revealing the molecular mechanism of cancer and developing new therapeutic strategies from a comprehensive perspective need to shift from identifying individual risk genes toward identifying risk protein complexes.</p>
    <p id="p0010">The study of protein complex is becoming an important means to reveal the molecular mechanism and guide drug development. To explore the molecular details of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells and develop drugs and vaccines against COVID-19, Krogan and co-workers characterized SARS-CoV-2-host protein complexes formed by the physical interactions between 26 SARS-CoV-2 proteins and human proteins using affinity-purification mass spectrometry, and identified 66 druggable human proteins targeted by 69 compounds, which may lead to a therapeutic regimen to treat COVID-19 <xref rid="b0065" ref-type="bibr">[13]</xref>. For human cancer, the role of some protein complexes in cancer has been revealed, such as the E-cadherin/catenin adhesion complex in the development and progression of cancer <xref rid="b0070" ref-type="bibr">[14]</xref>, the TWIST/Mi2/NuRD protein complex in cancer metastasis <xref rid="b0075" ref-type="bibr">[15]</xref>, the oncogenic Tcf/beta-catenin protein complex <xref rid="b0080" ref-type="bibr">[16]</xref> and the shelterin complex <xref rid="b0085" ref-type="bibr">[17]</xref>. Potential therapeutic strategies that target protein complexes rather than individual proteins are being revealed. For example, the CAV1-GLUT3 complex has been reported to be targeted by Atorvastatin to suppress tumor growth in non-small cell lung cancer <xref rid="b0090" ref-type="bibr">[18]</xref>. However, studying key protein complexes in cancer at the system level lacks reliable targets. To date, few methods have been proposed to identify risk protein complexes on a large scale. In our previous study, we proposed a protein complex-based prognostic model, PCLasso <xref rid="b0095" ref-type="bibr">[19]</xref>, which shows superior prognostic performance than those based on individual genes. PCLasso uses survival outcome as the dependent variable and embeds protein complexes into the group Lasso-Cox model to construct prognostic models, which identify risk protein complexes associated with survival outcomes. However, PCLasso is unable to deal with the classification problem and identify the risk protein complexes that distinguish tumors from non-tumors, which may play important roles in the occurrence and development of cancer.</p>
    <p id="p0015">In this study, we embed protein complexes into classification models under the regularized learning framework, and propose a protein complex-based, group Lasso-logistic (PCLassoLog) model toward accurate cancer classification and risk protein complex discovery. PCLassoLog is an extension of PCLasso tuned for protein complex-based classification problems. We apply PCLassoLog to the classification of lung adenocarcinoma (LUAD) and hepatocellular cancer (HCC) patients and prove that PCLassoLog has superior predictive performance than the Lasso-logistic model based on individual genes and is able to identify cancer-related risk protein complexes. In addition, we calculate selection probabilities and implement two other protein complex-based group selection models to complement PCLassoLog in identifying reliable risk protein complexes. Finally, PCLassoLog is used to discover risk protein complexes associated with cancer development in 12 cancer types and those associated with gene mutation in LUAD. These risk protein complexes may provide potential targets at the protein complex level for cancer research and guide the development of new therapeutic strategies.</p>
  </sec>
  <sec id="s0010">
    <label>2</label>
    <title>Materials and methods</title>
    <sec id="s0015">
      <label>2.1</label>
      <title>Datasets</title>
      <p id="p0020">We collected deep protein expression datasets (1424 tumors and 1060 non-tumors) for 12 cancer types including LUAD <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, HCC <xref rid="b0110" ref-type="bibr">[22]</xref>, clear cell renal cell carcinoma (ccRCC) <xref rid="b0115" ref-type="bibr">[23]</xref>, colon adenocarcinoma (COAD) <xref rid="b0120" ref-type="bibr">[24]</xref>, endometrial carcinoma (EC) <xref rid="b0125" ref-type="bibr">[25]</xref>, esophageal squamous cell carcinoma (ESCC) <xref rid="b0130" ref-type="bibr">[26]</xref>, glioblastoma (GBM) <xref rid="b0135" ref-type="bibr">[27]</xref>, gastric cancer (GC) <xref rid="b0140" ref-type="bibr">[28]</xref>, head-and-neck squamous cell carcinoma (HNSCC) <xref rid="b0145" ref-type="bibr">[29]</xref>, lung squamous cell carcinoma (LSCC) <xref rid="b0150" ref-type="bibr">[30]</xref>, ovarian cancer (OV) <xref rid="b0155" ref-type="bibr">[31]</xref>, and pancreatic ductal adenocarcinoma (PDAC) <xref rid="b0160" ref-type="bibr">[32]</xref> from recently published proteomics studies (<xref rid="t0005" ref-type="table">Table 1</xref>). The two protein expression datasets for LUAD were obtained from the studies of Gillette et al. <xref rid="b0100" ref-type="bibr">[20]</xref> and Xu et al. <xref rid="b0105" ref-type="bibr">[21]</xref>, and were named LUAD.Gillette.Prot and LUAD.Xu.Prot, respectively. We also obtained mRNA expression datasets of the same samples in these two studies and named them LUAD.Gillette.mRNA and LUAD.Xu.mRNA, respectively. In addition, we obtained three independent mRNA expression datasets for LUAD from the Gene Expression Omnibus (GEO) database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/" id="ir005">https://www.ncbi.nlm.nih.gov/geo/</ext-link>): GSE10072 <xref rid="b0165" ref-type="bibr">[33]</xref>, GSE19804 <xref rid="b0170" ref-type="bibr">[34]</xref>, and GSE19188 <xref rid="b0175" ref-type="bibr">[35]</xref>, denoted as LUAD-valid1, LUAD-valid2, and LUAD-valid3, respectively. For HCC, we obtained five independent mRNA expression datasets (GSE54236 <xref rid="b0180" ref-type="bibr">[36]</xref>, GSE76427 <xref rid="b0185" ref-type="bibr">[37]</xref>, GSE64041 <xref rid="b0190" ref-type="bibr">[38]</xref>, GSE47197, and GSE14520 <xref rid="b0195" ref-type="bibr">[39]</xref>) from the GEO database for verification, which were denoted as HCC-valid1, HCC-valid2, HCC-valid3, HCC-valid4, and HCC-valid5, respectively. In total, the mRNA expression data of 909 tumors and 794 non-tumors were obtained (<xref rid="t0005" ref-type="table">Table 1</xref>). Data processing and normalization were provided in <bold>Supplementary Text</bold>.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Details about the datasets used for the 12 cancer types.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cancer types</th><th>Source / GEO<break/>accession NO.</th><th>Quantitative method /<break/>Platform</th><th>Datasets</th><th>Expression profiles</th><th>NO. of tumors</th><th>NO. of<break/>non-tumors</th><th>NO. of proteins/ mRNAs</th></tr></thead><tbody><tr><td rowspan="7"><bold>LUAD</bold></td><td>Gillette et al. <xref rid="b0100" ref-type="bibr">[20]</xref></td><td>TMT 10-plex</td><td>LUAD.Gillette.Prot</td><td>Protein</td><td>110</td><td>101</td><td>7136</td></tr><tr><td>Xu et al. <xref rid="b0105" ref-type="bibr">[21]</xref></td><td>LFQ</td><td>LUAD.Xu.Prot</td><td>Protein</td><td>103</td><td>103</td><td>6594</td></tr><tr><td>Gillette et al. <xref rid="b0100" ref-type="bibr">[20]</xref></td><td>HiSeq4000</td><td>LUAD.Gillette.mRNA</td><td>mRNA</td><td>110</td><td>101</td><td>17,679</td></tr><tr><td>GSE140343 <xref rid="b0105" ref-type="bibr">[21]</xref></td><td>GPL20795</td><td>LUAD.Xu.mRNA</td><td>mRNA</td><td>51</td><td>49</td><td>15,340</td></tr><tr><td>GSE10072</td><td>GPL96</td><td>LUAD-valid1</td><td>mRNA</td><td>58</td><td>49</td><td>12,754</td></tr><tr><td>GSE19804</td><td>GPL570</td><td>LUAD-valid2</td><td>mRNA</td><td>60</td><td>60</td><td>21,298</td></tr><tr><td>GSE19188</td><td>GPL570</td><td>LUAD-valid3</td><td>mRNA</td><td>91</td><td>65</td><td>21,298</td></tr><tr><td rowspan="6"><bold>HCC</bold></td><td>Gao et al. <xref rid="b0110" ref-type="bibr">[22]</xref></td><td>TMT 11-plex</td><td>HCC</td><td>Protein</td><td>159</td><td>159</td><td>6478</td></tr><tr><td>GSE54236</td><td>GPL6480</td><td>HCC-valid1</td><td>mRNA</td><td>78</td><td>77</td><td>19,595</td></tr><tr><td>GSE76427</td><td>GPL10558</td><td>HCC-valid2</td><td>mRNA</td><td>115</td><td>52</td><td>34,693</td></tr><tr><td>GSE64041</td><td>GPL6244</td><td>HCC-valid3</td><td>mRNA</td><td>60</td><td>60</td><td>23,307</td></tr><tr><td>GSE47197</td><td>GPL16699</td><td>HCC-valid4</td><td>mRNA</td><td>61</td><td>61</td><td>16,390</td></tr><tr><td>GSE14520</td><td>GPL3921</td><td>HCC-valid5</td><td>mRNA</td><td>225</td><td>220</td><td>12,742</td></tr><tr><td><bold>ccRCC</bold></td><td>Clark et al. <xref rid="b0115" ref-type="bibr">[23]</xref></td><td>TMT 10-plex</td><td>ccRCC</td><td>Protein</td><td>110</td><td>84</td><td>7150</td></tr><tr><td><bold>COAD</bold></td><td>Vasaikar et al. <xref rid="b0120" ref-type="bibr">[24]</xref></td><td>TMT 10-plex</td><td>COAD</td><td>Protein</td><td>100</td><td>97</td><td>4376</td></tr><tr><td><bold>EC</bold></td><td>Dou et al. <xref rid="b0125" ref-type="bibr">[25]</xref></td><td>TMT 10-plex</td><td>EC</td><td>Protein</td><td>95</td><td>49</td><td>7908</td></tr><tr><td><bold>ESCC</bold></td><td>Liu et al. <xref rid="b0130" ref-type="bibr">[26]</xref></td><td>TMT 11-plex</td><td>ESCC</td><td>Protein</td><td>124</td><td>124</td><td>6461</td></tr><tr><td><bold>GBM</bold></td><td>Wang et al. <xref rid="b0135" ref-type="bibr">[27]</xref></td><td>TMT 11-plex</td><td>GBM</td><td>Protein</td><td>99</td><td>10</td><td>8828</td></tr><tr><td><bold>GC</bold></td><td>Ge et al. <xref rid="b0140" ref-type="bibr">[28]</xref></td><td>LFQ</td><td>GC</td><td>Protein</td><td>84</td><td>84</td><td>5439</td></tr><tr><td><bold>HNSCC</bold></td><td>Huang et al. <xref rid="b0145" ref-type="bibr">[29]</xref></td><td>TMT 11-plex</td><td>HNSCC</td><td>Protein</td><td>109</td><td>63</td><td>7515</td></tr><tr><td><bold>LSCC</bold></td><td>Satpathy et al. <xref rid="b0150" ref-type="bibr">[30]</xref></td><td>TMT 11-plex</td><td>LSCC</td><td>Protein</td><td>108</td><td>99</td><td>8218</td></tr><tr><td><bold>OV</bold></td><td>Hu et al. <xref rid="b0155" ref-type="bibr">[31]</xref></td><td>iTRAQ</td><td>OV</td><td>Protein</td><td>83</td><td>20</td><td>7599</td></tr><tr><td><bold>PDAC</bold></td><td>Cao et al. <xref rid="b0160" ref-type="bibr">[32]</xref></td><td>TMT 11-plex</td><td>PDAC</td><td>Protein</td><td>140</td><td>67</td><td>5755</td></tr></tbody></table><table-wrap-foot><fn><p>TMT: tandem mass tags-based isobaric labeling; LFQ: label-free quantification; iTRAQ: isobaric tag for relative and absolute quantitation; LUAD: lung adenocarcinoma; HCC: hepatocellular carcinoma; ccRCC: clear cell renal cell carcinoma; COAD: colon adenocarcinoma; EC: endometrial carcinoma; ESCC: esophageal squamous cell carcinoma; GBM: glioblastoma; GC: gastric cancer; HNSCC: head-and-neck squamous cell carcinoma; LSCC: lung squamous cell carcinoma; OV: ovarian cancer; PDAC: pancreatic ductal adenocarcinoma.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="s0020">
      <label>2.2</label>
      <title>Protein complexes</title>
      <p id="p0025">The protein complexes were obtained from the CORUM database (Release 3.0) <xref rid="b0035" ref-type="bibr">[7]</xref>. We chose to download the core set as it is a reduced dataset that is essentially free of redundant entries. The core set contains 3512 mammalian protein complexes, from which 2417 human protein complexes composed of 3420 unique proteins were selected for downstream analysis.</p>
    </sec>
    <sec id="s0025">
      <label>2.3</label>
      <title>Lasso-logistic model</title>
      <p id="p0030">Assume that we have a protein expression matrix <bold><italic>X</italic></bold> = [<bold><italic>x</italic></bold><sub>1</sub>, <bold><italic>x</italic></bold><sub>2</sub>, …, <bold><italic>x</italic></bold><italic><sub>n</sub></italic>] ∈ <italic>R<sup>n</sup></italic><sup>×</sup><italic><sup>p</sup></italic> and a vector of response variables <bold><italic>Y</italic></bold> = [<italic>y</italic><sub>1</sub>, <italic>y</italic><sub>2</sub>, …, <italic>y<sub>n</sub></italic>]<italic><sup>T</sup></italic> ∈ <italic>R<sup>n</sup></italic>, where <italic>n</italic> is the number of samples and <italic>p</italic> is the number of proteins. The <italic>i</italic>-th sample can be denoted as (<bold><italic>x</italic></bold><italic><sub>i</sub></italic>, <italic>y<sub>i</sub></italic>), where <bold><italic>x</italic></bold><italic><sub>i</sub></italic> ∈ <italic>R<sup>p</sup></italic> is its expression value vector and <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∈</mml:mo><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> is a binary response variable. Without loss of generality, we assume that <italic>y<sub>i</sub></italic> = 1 means that the sample is a tumor sample, and <italic>y<sub>i</sub></italic> = 0 means it is a non-tumor sample. Linear logistic regression models the condition probability <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> by<disp-formula id="e0005"><label>(1)</label><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M4" altimg="si4.svg"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> is the intercept and <inline-formula><mml:math id="M5" altimg="si5.svg"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>=</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mo>∈</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> is the parameter vector. Then we have<disp-formula id="e0010"><label>(2)</label><mml:math id="M6" altimg="si6.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p>
      <p id="p0035">For logistic regression model, the likelihood function is:<disp-formula id="e0015"><label>(3)</label><mml:math id="M7" altimg="si7.svg"><mml:mrow><mml:mi>L</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msup><mml:msup><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      <p id="p0040">Substituting <xref rid="e0010" ref-type="disp-formula">(2)</xref> into <xref rid="e0015" ref-type="disp-formula">(3)</xref> and taking the logarithm, we obtain the log-likelihood function:<disp-formula id="e0020"><label>(4)</label><mml:math id="M8" altimg="si8.svg"><mml:mrow><mml:mi>L</mml:mi><mml:mi>L</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      <p id="p0045">The regression coefficients <inline-formula><mml:math id="M9" altimg="si9.svg"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> can be estimated by maximizing the log-likelihood function <xref rid="e0020" ref-type="disp-formula">(4)</xref>. This is equivalent to solving the following problem:<disp-formula id="e0025"><label>(5)</label><mml:math id="M10" altimg="si10.svg"><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      <p id="p0050">In the high-dimensional setting (<italic>p</italic> ≫ <italic>n</italic>), directly solving the problem <xref rid="e0025" ref-type="disp-formula">(5)</xref> is ill-posed. The Lasso-logistic model can effectively solve this problem by including a regularization term:<disp-formula id="e0030"><label>(6)</label><mml:math id="M11" altimg="si11.svg"><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M12" altimg="si12.svg"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> is a control parameter and <inline-formula><mml:math id="M13" altimg="si13.svg"><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mrow><mml:mspace width="0.166667em"/><mml:mo>·</mml:mo><mml:mspace width="0.166667em"/></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> is the <italic>l</italic><sub>1</sub> norm. It generates a sparse solution <inline-formula><mml:math id="M14" altimg="si14.svg"><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub><mml:mtext>,</mml:mtext><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo stretchy="true" mathvariant="bold">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> with only a few nonzero coefficients <italic>β<sub>k</sub></italic>s, corresponding to the proteins selected. Then the probability that a new sample is a tumor sample can be estimated by:<disp-formula id="e0035"><label>(7)</label><mml:math id="M15" altimg="si15.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo stretchy="true" mathvariant="bold">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo stretchy="true" mathvariant="bold">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>where <bold><italic>x</italic></bold> is the protein expression vector of the new sample. Given a threshold <italic>th</italic>, the new sample is predicted to be a tumor sample if <inline-formula><mml:math id="M16" altimg="si16.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="|"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⩾</mml:mo><mml:mi>t</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:math></inline-formula> and a non-tumor sample otherwise. In this study, <italic>th</italic> = 0.5 was used. As important predictors, proteins with nonzero coefficients can be considered as potential risk proteins for further investigation.</p>
    </sec>
    <sec id="s0030">
      <label>2.4</label>
      <title>Protein complex-based, group Lasso-logistic model</title>
      <p id="p0055">Note that the Lasso-logistic model is similar to the Lasso-Cox model <xref rid="b0095" ref-type="bibr">[19]</xref> except for the log likelihood function (the first term in equation <xref rid="e0030" ref-type="disp-formula">(6)</xref>). We use the same strategy as PCLasso to integrate protein complexes into the regularized learning framework <xref rid="e0030" ref-type="disp-formula">(6)</xref> and propose a protein complex-based, group Lasso-logistic model (PCLassoLog) to predict the class of samples and identify risk protein complexes. The group Lasso-logistic model for nonoverlapping groups can be formulated as follows <xref rid="b0200" ref-type="bibr">[40]</xref>:<disp-formula id="e0040"><label>(8)</label><mml:math id="M17" altimg="si17.svg"><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msqrt><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:mrow><mml:mfenced open="∥" close="∥"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M18" altimg="si18.svg"><mml:mrow><mml:mfenced open="∥" close="∥"><mml:mrow><mml:mrow><mml:mspace width="0.166667em"/><mml:mo>·</mml:mo><mml:mspace width="0.166667em"/></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> is the Euclidean norm or <italic>l</italic><sub>2</sub> norm, <inline-formula><mml:math id="M19" altimg="si19.svg"><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> is the size of the <italic>k</italic>-th group, and <inline-formula><mml:math id="M20" altimg="si20.svg"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:msub><mml:mo>∈</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is a coefficient vector of the <italic>k</italic>-th group (<xref rid="s0135" ref-type="sec">Fig. S1</xref><bold>A</bold>). PCLassoLog deals with the overlap problem of protein complexes by using a latent group Lasso method <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>:<disp-formula id="e0045"><label>(9)</label><mml:math id="M21" altimg="si21.svg"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msqrt><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:mrow><mml:mfenced open="∥" close="∥"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">γ</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>t</mml:mi><mml:mo>.</mml:mo><mml:mspace width="1em"/><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">γ</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where equation <inline-formula><mml:math id="M22" altimg="si22.svg"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">γ</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> means that <bold><italic>β</italic></bold> is decomposed into the sum of <italic>K</italic> latent vectors<inline-formula><mml:math id="M23" altimg="si23.svg"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">γ</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>=</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi mathvariant="italic">kp</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mo>∈</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mi>K</mml:mi></mml:mrow></mml:math></inline-formula>, whose supports correspond to the proteins contained in each protein complex, i.e., <inline-formula><mml:math id="M24" altimg="si24.svg"><mml:mrow><mml:mtext>supp</mml:mtext><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">γ</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⊂</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (<xref rid="s0135" ref-type="sec">Fig. S1</xref><bold>B</bold>). PCLassoLog is solved in the same way as PCLasso <xref rid="b0095" ref-type="bibr">[19]</xref> (see <bold>Supplementary Text</bold>).</p>
    </sec>
    <sec id="s0035">
      <label>2.5</label>
      <title>Other group selection methods</title>
      <p id="p0060">In addition to the Lasso penalty, we investigated other two penalties, namely smoothly clipped absolute deviation penalty (SCAD) <xref rid="b0215" ref-type="bibr">[43]</xref> and minimax concave penalty (MCP) <xref rid="b0220" ref-type="bibr">[44]</xref>. The two penalties add an additional parameter <italic>a</italic> for relaxing the penalties, and are defined for <italic>λ</italic> &gt; 0 as follows:<disp-formula id="e0050"><label>(10)</label><mml:math id="M25" altimg="si25.svg"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">SCAD</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:mrow><mml:mfenced open="{"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>λ</mml:mi><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="italic">if</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⩽</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>a</mml:mi><mml:mi>λ</mml:mi><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="italic">if</mml:mi><mml:mspace width="0.277778em"/><mml:mi>λ</mml:mi><mml:mo>&lt;</mml:mo><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⩽</mml:mo><mml:mi>a</mml:mi><mml:mi>λ</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:msup><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="italic">if</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&gt;</mml:mo><mml:mi>a</mml:mi><mml:mi>λ</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="e0055"><label>(11)</label><mml:math id="M26" altimg="si26.svg"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">MCP</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:mrow><mml:mfenced open="{"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>λ</mml:mi><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mn>2</mml:mn><mml:mi>a</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="italic">if</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⩽</mml:mo><mml:mi>a</mml:mi><mml:mi>λ</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:msup><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="italic">if</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&gt;</mml:mo><mml:mi>a</mml:mi><mml:mi>λ</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic>a</italic> &gt; 2 for SCAD and <italic>a</italic> &gt; 1 for MCP.</p>
      <p id="p0065">Among the three penalties, the Lasso is the largest, followed by SCAD, and MCP is the smallest (<xref rid="s0135" ref-type="sec">Figure S2</xref>). The protein complex-based, group SCAD-logistic model (PCSCAD) and group MCP-logistic model (PCMCP) are defined by replacing the Lasso penalty in PCLassoLog with SCAD and MCP penalties, respectively (see <bold>Supplementary Text</bold>).</p>
    </sec>
    <sec id="s0040">
      <label>2.6</label>
      <title>Model evaluation and selection probability</title>
      <p id="p0070">The area under the ROC curve (AUC) and classification accuracy were used to evaluate classification performance. To obtain an unbiased evaluation, we adopted a resampling strategy. Let <italic>I<sub>m</sub></italic> be the <italic>m</italic>-th random subsample of <inline-formula><mml:math id="M27" altimg="si27.svg"><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> of size <inline-formula><mml:math id="M28" altimg="si28.svg"><mml:mrow><mml:mfenced open="⌊" close="⌋"><mml:mrow><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow><mml:mo stretchy="true">/</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> without replacement, where <inline-formula><mml:math id="M29" altimg="si29.svg"><mml:mrow><mml:mfenced open="⌊" close="⌋"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> is the largest integer not greater than <italic>x</italic>,<inline-formula><mml:math id="M30" altimg="si30.svg"><mml:mrow><mml:mi>m</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>. Each <italic>I<sub>m</sub></italic> was used as a training set to train the model. Then the AUCs and classification accuracies of each model on the corresponding test set <inline-formula><mml:math id="M31" altimg="si31.svg"><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mfenced><mml:mrow><mml:mo stretchy="true">\</mml:mo></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and independent validation datasets were estimated. All <italic>M</italic> AUCs and accuracies were used to evaluate the overall predictive performance of the model. For each training set <italic>I<sub>m</sub></italic>, cross-validation was used to determine the optimal <italic>λ</italic> value, denoted as <italic>λ<sub>m</sub></italic>. For the PCSCAD and PCMCP model, a series of <italic>a</italic>-values of 4, 6, 8, …, 500 were investigated.</p>
      <p id="p0075">To identify reliable risk protein complexes, we define the selection probability (SP) of the <italic>k</italic>-th protein complex according to the stability selection theory <xref rid="b0225" ref-type="bibr">[45]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref> as follow:<disp-formula id="e0060"><mml:math id="M32" altimg="si32.svg"><mml:mrow><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>M</mml:mi></mml:mfrac><mml:mo>#</mml:mo><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>:</mml:mo><mml:mi>k</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:msub><mml:mi>λ</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      <p id="p0080">where <inline-formula><mml:math id="M33" altimg="si33.svg"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:msub><mml:mi>λ</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo>⊂</mml:mo><mml:mrow><mml:mfenced open="{" close="}"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mi>K</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> denotes the protein complexes selected by PCLassoLog when applied to subsample <italic>I<sub>m</sub></italic>. Selection probabilities give a confidence measure for risk protein complexes (see <bold>Supplementary Text</bold>).</p>
    </sec>
  </sec>
  <sec id="s0045">
    <label>3</label>
    <title>Results</title>
    <sec id="s0050">
      <label>3.1</label>
      <title>Overview of the PCLassoLog model</title>
      <p id="p0085">The PCLassoLog model is a classification model that selects important predictors at the protein complex level to achieve accurate classification and identify risk protein complexes. The PCLassoLog model has three inputs: a protein expression matrix, a vector of binary response variables, and a number of known protein complexes (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Considering that proteins usually function by forming protein complexes, PCLassoLog regards proteins belonging to the same protein complex as a group and constructs a group Lasso penalty (<italic>l</italic><sub>1</sub>/<italic>l</italic><sub>2</sub> penalty) based on the sum (i.e. <italic>l</italic><sub>1</sub> norm) of the <italic>l</italic><sub>2</sub> norms of the regression coefficients of the group members to perform feature selection at the group level <xref rid="b0205" ref-type="bibr">[41]</xref>. With the group Lasso penalty, PCLassoLog trains the logistic regression model and obtains a sparse solution at the protein complex level, that is, the proteins belonging to a protein complex are either wholly included or wholly excluded from the model. PCLassoLog outputs a prediction model and a small set of protein complexes included in the model, which are referred to as risk protein complexes (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). For further details, see Materials and Methods.<fig id="f0005"><label>Fig. 1</label><caption><p>Workflow of the PCLassoLog model. The PCLassoLog model takes a protein expression matrix, a binary response variable vector, and a collection of protein complexes as input. It estimates the correlation between protein expression and the response variable, and performs feature selection at the protein complex level. PCLassoLog outputs a prediction model for the classification of new patients and risk protein complexes of the disease.</p></caption><graphic xlink:href="gr1"/></fig></p>
    </sec>
    <sec id="s0055">
      <label>3.2</label>
      <title>PCLassoLog yields superior predictive performance based on protein complexes</title>
      <p id="p0090">To evaluate the classification performance of PCLassoLog and its ability to identify risk protein complexes, we constructed the PCLassoLog model based on three protein expression datasets: LUAD.Gillette.Prot, LUAD.Xu.Prot, and HCC (<xref rid="t0005" ref-type="table">Table 1</xref>). For the convenience of description, we will refer to the experiments based on the three datasets as the “LUAD.Gillette.Prot”, “LUAD.Xu.Prot”, and “HCC” cases, respectively. For each case, we used a training set to construct the PCLassoLog model and used a test set and multiple independent validation sets to evaluate classification accuracy and robustness. The samples in the test set are similar to those in the training set, while the samples of the validation sets are completely independent of the training set, and different platforms may be used, which could better verify the robustness of PCLassoLog (<xref rid="t0005" ref-type="table">Table 1</xref>). The AUCs and classification accuracies were calculated to evaluate classification performance. We also performed the individual protein-based Lasso-logistic model following the same procedure and compared the classification performance of the two models.</p>
      <sec id="s0060">
        <label>3.2.1</label>
        <title>LUAD.Gillette.Prot</title>
        <p id="p0095">Two independent protein expression datasets for LUAD were collected. We first trained the PCLassoLog model using the LUAD.Gillette.Prot dataset. The LUAD.Gillette.Prot dataset was randomly split into a training set (LUAD.Gillette.Prot–train, <italic>n</italic> = 140) and a test set (LUAD.Gillette.Prot–test, <italic>n</italic> = 71), keeping the ratio of the number of tumors to non-tumors in the test set the same as that in the training set. The PCLassoLog model trained on the LUAD.Gillette.Prot–train dataset (see <bold>Supplementary Text</bold>) contained 17 protein complexes composed of 34 proteins (<xref rid="f0010" ref-type="fig">Fig. 2</xref><bold>A-C</bold>; <xref rid="s0135" ref-type="sec">Table S1</xref>). Many proteins belonging to these 17 protein complexes have been reported to play critical role in tumorigenicity or promote the proliferation, metastasis, and invasion of LUAD, such as ILK <xref rid="b0240" ref-type="bibr">[48]</xref>, PARVA <xref rid="b0245" ref-type="bibr">[49]</xref>, AQP4 <xref rid="b0250" ref-type="bibr">[50]</xref>, and PRKCI <xref rid="b0255" ref-type="bibr">[51]</xref>. The Lasso-logistic model selected 25 individual proteins (<xref rid="s0135" ref-type="sec">Fig. S3</xref><bold>A</bold>; <xref rid="s0135" ref-type="sec">Table S2</xref>). Some proteins identified by the Lasso-logistic model were shared by PCLassoLog, but without the information at the protein complex level. Both models achieved perfect classification on the LUAD.Gillette.Prot-test dataset, and were almost perfect on the independent protein expression dataset LUAD.Xu.Prot, with the AUC of PCLassoLog slightly larger (<xref rid="f0010" ref-type="fig">Fig. 2</xref><bold>D</bold>).<fig id="f0010"><label>Fig. 2</label><caption><p>Classification of LUAD patients based on models constructed on the LUAD.Gillette.Prot dataset. (A) Plot of cross-validation errors. Each point represents the cross-validation error of a λ value, with error bars to give a confidence interval for the cross-validation errors. The vertical bar indicates the λ value corresponding to the final model we selected. The top of the plot gives the size of each model at the group (protein complex) level and the individual protein level. (B) Norms of the coefficient vectors of the protein complexes. The complex IDs of the six protein complexes with the largest norm are shown on the right. (C) Coefficient paths of individual proteins. The proteins corresponding to the protein complexes in (B) are shown on the right. Proteins belonging to the same protein complex were selected into the model at the same time. (D-F) ROC curves of the PCLassoLog and Lasso-logistic models on two protein expression datasets (D), two matched mRNA expression datasets (E), and three independent mRNA expression datasets (F). (G) Classification accuracies of the PCLassoLog and Lasso-logistic models on the seven datasets. 1: LUAD.Gillette.Prot-test; 2: LUAD.Xu.Prot; 3: LUAD.Gillette.mRNA; 4: LUAD.Xu.mRNA; 5: LUAD-valid1; 6: LUAD-valid2; 7: LUAD-valid3.</p></caption><graphic xlink:href="gr2"/></fig></p>
        <p id="p0100">Next, we verified the classification performance of PCLassoLog on more independent datasets. Due to the lack of protein expression data at present, we tried to use mRNA expression data as a proxy. We first investigated the mRNA expression data in the LUAD.Gillette.mRNA dataset, which were measured on the same samples as the LUAD.Gillette.Prot dataset. Correlation analysis based on the common 1037 protein complexes found that 99.5 % sample-wise protein-mRNA pairs and 83.3 % gene-wise protein-mRNA pairs show significant positive Spearman correlations (BH adjusted p value &lt; 0.05) (<xref rid="s0135" ref-type="sec">Fig. S4</xref><bold>A</bold>). Among the 34 proteins contained in PCLassoLog, 31 (91.2 %) proteins have significant positive correlations (<xref rid="s0135" ref-type="sec">Table S1</xref>), such as ILK, PARVA, FHL2, and FHL5 (<xref rid="s0135" ref-type="sec">Fig. S4</xref><bold>B-4C</bold>), suggesting that mRNA expression data may be a feasible proxy for protein expression data. Indeed, both PCLassoLog and Lasso-logistic achieved almost perfect classification on the LUAD.Gillette.mRNA dataset (<xref rid="f0010" ref-type="fig">Fig. 2</xref><bold>E</bold>). For other four mRNA datasets, the AUCs obtained by PCLassoLog are larger than those of the Lasso-logistic model, as well as classification accuracies (<xref rid="f0010" ref-type="fig">Fig. 2</xref><bold>E-G</bold>).</p>
      </sec>
      <sec id="s0065">
        <label>3.2.2</label>
        <title>LUAD.Xu.Prot</title>
        <p id="p0105">We next constructed a PCLassoLog model with 18 protein complexes / 36 proteins (<xref rid="s0135" ref-type="sec">Fig. S5</xref><bold>A-C</bold>; <xref rid="s0135" ref-type="sec">Table S3</xref>) and a Lasso-logistic model with 27 proteins (<xref rid="s0135" ref-type="sec">Fig. S3</xref><bold>B</bold>; <xref rid="s0135" ref-type="sec">Table S4</xref>) based on the LUAD.Xu.Prot dataset following the same procedure as above (see <bold>Supplementary Text</bold>). PCLassoLog and Lasso-logistic yielded comparable AUCs on the LUAD.Xu.Prot–test dataset and the independent protein expression dataset LUAD.Gillette.Prot (<xref rid="s0135" ref-type="sec">Fig. S5</xref><bold>D</bold>). Considering the significant positive correlation of protein-mRNA pairs between LUAD.Xu.Prot and LUAD.Xu.mRNA datasets (<xref rid="s0135" ref-type="sec">Fig. S4</xref><bold>D-F</bold>; <xref rid="s0135" ref-type="sec">Table S3</xref>), we further evaluated the performance of PCLassoLog on the mRNA expression datasets. PCLassoLog obtained larger AUCs than those of the Lasso-logistic model on all the two matched mRNA expression datasets and three independent datasets (<xref rid="s0135" ref-type="sec">Fig. S5</xref><bold>E-F</bold>). The classification accuracies showed the same trend (<xref rid="s0135" ref-type="sec">Fig. S5</xref><bold>G</bold>).</p>
      </sec>
      <sec id="s0070">
        <label>3.2.3</label>
        <title>HCC</title>
        <p id="p0110">We further constructed a PCLassoLog model with 18 protein complexes / 35 proteins (<xref rid="s0135" ref-type="sec">Figure S6</xref><bold>A-C</bold>; <xref rid="s0135" ref-type="sec">Table S5</xref>) and a Lasso-logistic model with 24 proteins (<xref rid="s0135" ref-type="sec">Fig. S3</xref><bold>C</bold>; <xref rid="s0135" ref-type="sec">Table S6</xref>) based on the HCC dataset (see <bold>Supplementary Text</bold>). Both PCLassoLog and Lasso-logistic models achieved perfect classification on the HCC–test dataset (<xref rid="s0135" ref-type="sec">Figure S6</xref><bold>D</bold>). The AUCs of PCLassoLog on the five independent datasets were all larger than those of the Lasso-logistic model (<xref rid="s0135" ref-type="sec">Figure S6</xref><bold>D</bold>), as well as the classification accuracies (<xref rid="s0135" ref-type="sec">Figure S6</xref><bold>E</bold>), which further confirms the superior predictive performance of PCLassoLog.</p>
      </sec>
    </sec>
    <sec id="s0075">
      <label>3.3</label>
      <title>PCLassoLog produces discriminative and robust features at the level of protein complexes</title>
      <p id="p0115">Next, we looked into the PCLassoLog and Lasso-logistic models, and tried to explore the reasons why PCLassoLog could outperform the Lasso-logistic model by comparing the features selected by the two models. For the two LUAD protein expression datasets, the two models share seven (<xref rid="s0135" ref-type="sec">Table S1</xref>) and eight (<xref rid="s0135" ref-type="sec">Table S3</xref>) proteins, respectively. The difference is that Lasso-logistic only selects individual proteins, while PCLassoLog selects all proteins that are present in the protein complex containing it. We focused on these shared proteins for comparison. For the “LUAD.Gillette.Prot” case, the seven shared proteins belong to six protein complexes. To compare the discriminative ability and robustness of features, we calculated the <italic>t</italic>-statistics of the six protein complexes (see <bold>Supplementary Text</bold> for the definition of the <italic>t</italic>-statistic of the protein complex) and their member proteins in all the eight datasets (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>A</bold>). The larger absolute value of <italic>t</italic>-statistic reflects stronger discriminative ability. Proteins that were consistently up-regulated (e.g., FHL2; unpaired two-sided <italic>t</italic>-test, <italic>t</italic>-statistic &gt; 0, p &lt; 0.05; points colored in red) or down-regulated (e.g., FHL5 and TLN1; unpaired two-sided <italic>t</italic>-test, <italic>t</italic>-statistic &lt; 0, p &lt; 0.05; points colored in cyan) across all datasets help the prediction models achieve robust predictive performance on independent datasets. In contrast, proteins with inconsistent expression levels across datasets (e.g., VIM) may reduce the robustness of prediction models, especially the Lasso-logistic model based on individual proteins.<fig id="f0015"><label>Fig. 3</label><caption><p>Comparison of the protein complexes selected by PCLassoLog and the proteins selected by Lasso-logistic. (A) The “LUAD.Gillette.Prot” case. (B) The “LUAD.Xu.Prot” case. The proteins shown in red were selected by both models. The x-axis represents <italic>t</italic>-statistics. <italic>P</italic> values were calculated by unpaired two-sided Student’s <italic>t</italic>-test. Red points indicate that the expression of these proteins is significantly up-regulated in tumor samples, while cyan points indicate significant down-regulation (BH adjusted <italic>p</italic> value &lt; 0.05). Grey means no significant difference. For each protein complex, “Complex” represents a pseudo-protein constructed by a linear combination of proteins contained in this protein complex, where the coefficients of the linear combination are obtained from the PCLassoLog model. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0120">The features at the protein complex level tend to be more discriminative. For example, for the “LUAD.Gillette.Prot” case, the <italic>t</italic>-statistic of the FHL2-ACT complex increased by 42.4 %, 81.3 %, 41.2 %, 78.3 %, 38.8 %, 59.0 %, 58.9 %, and 104.6 % in the eight datasets compared with the <italic>t</italic>-statistic of FHL2 (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>A</bold>). For the “LUAD.Xu.Prot” case, the <italic>t</italic>-statistic of the Ku antigen-NARG1 complex increased by 11.2 %, 21.0 %, 44.7 %, 34.8 %, 37.3 %, 46.6 %, 20.4 %, and 21.0 % in the eight datasets compared with the <italic>t</italic>-statistic of XRCC6 (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>B</bold>). Other examples include SMN complex vs SNRPA, ITGA2b-ITGB3-TLN1 complex vs TLN1 for the “LUAD.Gillette.Prot” case (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>A</bold>), and PLOD2-FKBP10 complex vs PLOD2 for the “LUAD.Xu.Prot” case (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>B</bold>). Furthermore, the features at the protein complex level tend to be more robust. For example, the SMN complex was consistently up-regulated across all eight datasets, but SNRPA did not show a significant up-regulation in the LUAD.Xu.mRNA dataset (<xref rid="f0015" ref-type="fig">Fig. 3</xref><bold>A</bold>). These two trends may lead to the superiority of the PCLassoLog model based on protein complexes over the Lasso-logistic model based on individual proteins.</p>
    </sec>
    <sec id="s0080">
      <label>3.4</label>
      <title>PCLassoLog produces better overall predictive performance</title>
      <p id="p0125">To show that the superior predictive performance of PCLassoLog does not depend on the specific division of the dataset, we performed 100 random divisions on the LUAD.Gillette.Prot, LUAD.Xu.Prot, and HCC datasets, respectively. For each division, we used the same strategy as the above experiments to construct classification models and evaluate predictive performance. We trained 100 models for each of these three datasets (<xref rid="s0135" ref-type="sec">Figure S7</xref>). Then the resulting 100 AUCs and 100 classification accuracies obtained on each dataset were used to evaluate the overall predictive performance.</p>
      <p id="p0130">For the “LUAD.Gillette.Prot” case, except for the LUAD.Gillette.Prot-test dataset, the AUCs and classification accuracies obtained by PCLassoLog on the other six datasets are significantly higher than those of the Lasso-logistic model (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>A</bold>). For the “LUAD.Xu.Prot” case, the predictive performance of PCLassoLog on the two protein expression datasets and two matched mRNA expression datasets is comparable to that of the Lasso-logistic model, while the AUCs and classification accuracies obtained on the three independent datasets are again significantly higher than those of the Lasso-logistic model (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>B</bold>). For the “HCC” case, except for the HCC-test dataset, the AUCs and classification accuracies of PCLassoLog on the five independent datasets are significantly higher than those of the Lasso-logistic model (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>C</bold>), further confirming the better prediction performance of PCLassoLog.<fig id="f0020"><label>Fig. 4</label><caption><p>Comparison of overall prediction performance between PCLassoLog and Lasso-logistic. (A-C) The prediction performance of PCLassoLog and Lasso-logistic models in the “LUAD.Gillette.Prot” case (A), the “LUAD.Xu.Prot” case (B), and the “HCC” case (C). Left: AUC; Right: classification accuracy. For each case, 100 models are constructed based on the training set. Each box is plotted based on 100 AUCs/accuracies, which are calculated using the prediction results of the 100 models. The middle bar represents the median, and the box represents the interquartile range; bars extend to 1.5 × the interquartile range. <italic>P</italic> values are calculated by the two-sided Wilcoxon rank-sum test. (D) Comparison of risk protein complexes and proteins identified in the LUAD.Gillette.Prot and LUAD.Xu.Prot datasets.</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0135">Next, we investigated the robustness of PCLassoLog in identifying risk protein complexes. From the 100 random divisions, PCLassoLog identified 69 and 98 risk protein complexes in the two datasets, respectively (<xref rid="s0135" ref-type="sec">Table S7 and S8</xref>). Of these, 29 (21 %) protein complexes were identified in both datasets (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>D</bold>). At the individual protein level, 53 (23 %) proteins were identified in both datasets. The overlap is almost twice that of the Lasso-Logistic model, where only 33 (12 %) proteins are shared between the two datasets (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>D</bold> and <xref rid="s0135" ref-type="sec">Table S9</xref>). This indicates that PCLassoLog has stronger robustness in identifying risk protein complexes than the traditional Lasso-logistic model in identifying risk proteins.</p>
    </sec>
    <sec id="s0085">
      <label>3.5</label>
      <title>Comparison with other protein complex-based methods</title>
      <p id="p0140">We next compared PCLassoLog with PCSCAD and PCMCP, which were constructed following the same procedure as described above for evaluating the overall predictive performance of PCLassoLog (see <bold>Supplementary Text</bold>). The number of protein complexes selected by the PCMCP model is less than that of PCSCAD, and PCSCAD is less than that of PCLassoLog (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>A, S9A, S10A</bold>), which is consistent with the successive reduction of penalties for large coefficients of these three models (<xref rid="s0135" ref-type="sec">Figure S2</xref>). PCLassoLog penalizes large coefficients the most, allowing more protein complexes to enter the model to minimize training errors. Indeed, when <italic>a</italic> is small, the average cross-validation errors of PCSCAD and PCMCP are greater than those of PCLassoLog in all the three datasets (<xref rid="s0135" ref-type="sec">Figure S11</xref>). As <italic>a</italic>→∞, the number of protein complexes included in the PCSCAD and PCMCP models and the cross-validation errors become close to those of PCLassoLog (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>A, S9A, S10A, S11</bold>), which is consistent with their penalty function approaching that of PCLassoLog as <italic>a</italic>→∞. At the individual protein level, PCSCAD and PCMCP contain fewer proteins than Lasso-logistic when <italic>a</italic> is small, and more than Lasso-logistic model as <italic>a</italic>→∞ (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>B, S9B, S10B</bold>).</p>
      <p id="p0145">The PCLassoLog, PCSCAD, PCMCP, and Lasso-logistic model obtained comparable performance on the LUAD.Gillette.Prot-test (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>C and S12A</bold>), LUAD.Xu.Prot-test (<xref rid="s0135" ref-type="sec">Figure S9</xref><bold>C and S13A</bold>), and HCC-test (<xref rid="s0135" ref-type="sec">Figure S10</xref><bold>C and S14A</bold>) datasets, indicating that all four models could achieve good prediction performance on homogeneous datasets. On the two independent protein expression datasets, LUAD.Xu.Prot (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>D, S12B</bold>) and LUAD.Gillette.Prot (<xref rid="s0135" ref-type="sec">Figure S9</xref><bold>D, S13B</bold>), PCLassoLog is superior to PCSCAD and PCMCP. This advantage is further observed on almost all mRNA expression datasets, including the five datasets in the “LUAD.Gillette.Prot” case (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>E-I</bold>, <bold>S12C-G</bold>), the five datasets in the “LUAD.Xu.Prot” case (<xref rid="s0135" ref-type="sec">Figure S9</xref><bold>E-I</bold>, <bold>S13C-G</bold>), and the five datasets in the “HCC” case (<xref rid="s0135" ref-type="sec">Figure S10</xref><bold>D-H</bold>, <bold>S14B-F</bold>). When <italic>a</italic> is large, the prediction performance of PCSCAD and PCMCP is close to that of PCLassoLog, which is also consistent with the penalty functions of PCSCAD and PCMCP approaching that of PCLassoLog as <italic>a</italic>→∞. Compared with Lasso-logistic model, the prediction performance of PCSCAD and PCMCP is poor when <italic>a</italic> is small. However, when <italic>a</italic> is large, the prediction performance of the two models is better than that of Lasso-logistic model (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>G-I</bold>, <bold>S9D-I</bold>, <bold>S10D</bold>, <bold>S10G-H</bold>, <bold>S12E-G</bold>, <bold>S13B-G, S14B</bold>, and <bold>S14E-F</bold>).</p>
      <p id="p0150">The penalty of PCSCAD and PCMCP for large coefficients increases with the increase of a, which is exemplified by the ITGA2b-ITGB3-TLN1 complex (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>J</bold>). The SP of ITGA2B-ITGB3-TLN1 complex gradually decreased with the increase of <italic>a</italic>, and finally stabilized at the SP of the ITGA2b-ITGB3-TLN1 complex in the PCLassoLog model (SP = 0.54) (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>J</bold>). PCSCAD had the same trend as PCMCP, except that the SP of ITGA2B-ITGB3-TLN1 complex decreased faster, which could be attributed to the penalty of PCSCAD being larger than that of PCMCP (<xref rid="s0135" ref-type="sec">Figure S2</xref>). This indicates that the penalty strategies of the models are effective.</p>
      <p id="p0155">To compare the robustness of the three protein complex-based models in identifying risk protein complexes, we calculated the Jaccard coefficients of the sets of risk protein complexes identified by the three models on the two LUAD datasets to compare the overlap between them. The Jaccard coefficients of both PCSCAD and PCMCP are smaller than that of PCLassoLog (0.210) (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>K</bold>). The Jaccard coefficients of PCMCP are not stable, and are slightly smaller than those of PCSCAD for most <italic>a</italic> values (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>K</bold>). At the individual protein level, the Jaccard coefficients of all three protein complex-based models are greater than that of the Lasso-logistic model (0.123) (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>L</bold>), even though the number of risk proteins identified by PCSCAD and PCMCP is less than that of the Lasso-logistic model (<xref rid="s0135" ref-type="sec">Figure S8</xref><bold>B</bold>). This further confirms the robustness of the protein complex-based models in identifying risk protein complexes.</p>
      <p id="p0160">In addition, to estimate the risk of false positive results, we permutated the class labels of the LUAD.Gillette.Prot-train, LUAD.Xu.Prot-train, and HCC-trian datasets, and reconstructed the three protein complex-based models. Results show that the AUCs and accuracies obtained by the three models on all datasets are around 0.5, which is not better than random guessing (<xref rid="s0135" ref-type="sec">Figure S15</xref>), indicating that the prediction results of the three models are reliable.</p>
    </sec>
    <sec id="s0090">
      <label>3.6</label>
      <title>PCLassoLog identifies risk protein complexes</title>
      <p id="p0165">We next examined the top 10 risk protein complexes with the highest SP identified by PCLassoLog in the LUAD and HCC datasets (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0135" ref-type="sec">Table S10</xref><bold>A-B</bold>). The FHL2-ACT complex was identified as a risk protein complex with a SP of 1 in both the LUAD.Gillette.Prot and LUAD.Xu.Prot datasets (<xref rid="s0135" ref-type="sec">Table S7-S8</xref>). Both FHL2 and FHL5 in the FHL2-ACT complex belong to the FHL protein family of transcriptional cofactors. Another protein complex related to the FHL protein family, FHL2-FHL3 complex, also obtained a SP of 0.63 (<xref rid="t0010" ref-type="table">Table 2</xref>). FHL proteins could interact with important regulators of cancer development and progression, such as Smad2, Smad3, and Smad4, and suppress tumor cell growth through a TGF-β–like signaling pathway <xref rid="b0260" ref-type="bibr">[52]</xref>. Numerous studies have reported that FHL2 might act as a cell type specific oncoprotein or tumor suppressor in human cancers <xref rid="b0265" ref-type="bibr">[53]</xref>, such as gastrointestinal cancer <xref rid="b0270" ref-type="bibr">[54]</xref>, glioblastoma <xref rid="b0275" ref-type="bibr">[55]</xref>, and liver cancer <xref rid="b0260" ref-type="bibr">[52]</xref>. FHL3 is down-regulated in liver and breast cancer patients and could suppress cancer cell growth in these two cancer types <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>. Strikingly, FHL2 and FHL3 are significantly up-regulated in all seven LUAD datasets (<xref rid="s0135" ref-type="sec">Figure S16</xref><bold>A-B</bold>), while FHL5 is significantly down-regulated (<xref rid="s0135" ref-type="sec">Figure S16</xref><bold>C</bold>), suggesting that FHL proteins and their synergy may play important roles in the development of LUAD.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Risk protein complexes identified by PCLassoLog in the LUAD datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>NO.</th><th>ID</th><th>Complex Name</th><th>Gene Symbol</th><th>SP<sup>a</sup></th><th>Reference (PMID)<sup>c</sup></th></tr></thead><tbody><tr><td><bold>1</bold></td><td>3188</td><td>FHL2-ACT complex</td><td><bold>FHL2</bold><sup>b</sup>; <bold>FHL5</bold></td><td>1</td><td>FHL2: 19139564; 17352216; 17383428; 18615633; 19,139,564</td></tr><tr><td><bold>2</bold></td><td>5385</td><td>GAIT complex</td><td>SYNCRIP; <bold>GAPDH</bold>; <bold>EPRS</bold>; RPL13A</td><td>1</td><td>GAPDH: 25859407; 33029490; 26541605; EPRS: 27612429; 21941282; 33,740,160</td></tr><tr><td><bold>3</bold></td><td>7265</td><td>MLC1-Na, K-ATPase-Kir4.1-AQP4-TRPV4-syntrophin complex</td><td><bold>ATP1B1</bold>; <bold>AQP4</bold>; KCNJ10; MLC1; TRPV4; SNTG1</td><td>1</td><td>ATP1B1: 17471453; 20460749; AQP4: 21548930; 22372348; 27516192; 22105864; 22808259; 19,112,001</td></tr><tr><td><bold>4</bold></td><td>280</td><td>HMGB1-HMGB2-HSC70-ERP60-GAPDH complex</td><td><bold>GAPDH</bold>; HMGB1; HSPA8; HMGB2; <bold>PDIA3</bold></td><td>0.97</td><td>GAPDH: 25859407; 33029490; 26541605; PDIA3: 29228584; 20035634; 26125904; 28101228; 26,004,124</td></tr><tr><td><bold>5</bold></td><td>2422</td><td>ITGA4-ITGB1-JAM2 complex</td><td><bold>ITGB1</bold>; ITGA4; <bold>JAM2</bold></td><td>0.95</td><td>ITGB1: 23441154; 28656629; 26509963; 26766915; 26903137; JAM2: 29575013; 27588115; 26,782,073</td></tr><tr><td><bold>6</bold></td><td>2378</td><td>ITGA2b-ITGB3-TLN1 complex</td><td>ITGB3; <bold>ITGA2B</bold>; <bold>TLN1</bold></td><td>0.94</td><td>ITGA2B: 31523198; 26198048; TLN1: 31068760; 23,722,670</td></tr><tr><td><bold>7</bold></td><td>1737</td><td>SF3b complex</td><td>SF3B1; <bold>SF3B2</bold>; SF3B3; SF3B4; PHF5A; DDX42; <bold>SF3B5</bold>; SF3B6</td><td>0.94</td><td>SF3B2: 31,431,456</td></tr><tr><td><bold>8</bold></td><td>1085</td><td>DNA repair complex NEIL2-PNK-Pol (beta) -LigIII (alpha)-XRCC1</td><td><bold>PDXK</bold>; <bold>POLB</bold>; XRCC1; LIG3; NEIL2</td><td>0.9</td><td>PDXK: 22854025; 26387143; 32696745; POLB: 19330779; 25561897; 12,126,515</td></tr><tr><td><bold>9</bold></td><td>5465</td><td>IKB (epsilon)-RELA-cREL complex</td><td><bold>NFKBIE</bold>; RELA; <bold>REL</bold></td><td>0.89</td><td>NFKBIE: 27670424; REL: 10602468; 939994; 12,430,173</td></tr><tr><td><bold>10</bold></td><td>5862</td><td>CAV1-VDAC1-ESR1 complex</td><td>ESR1; <bold>VDAC1</bold>; <bold>CAV1</bold></td><td>0.87</td><td>VDAC1: 23233904; 31364685; 22204343; 24781191; 29682501; 21315184; 23663973; 21297950; 27304056; CAV1: 15205342; 31534543; 15692148; 29080835; 30,604,627</td></tr></tbody></table><table-wrap-foot><fn><p>Shown are the top 10 risk protein complexes with the highest SP. The full list of risk protein complexes is provided in <bold>Table S10A</bold>. <sup>a</sup>Selection probability; <sup>b</sup>Proteins shown in bold are detected in the LUAD datasets; <sup>c</sup>References related to the detected proteins in LUAD or other cancer types.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Risk protein complexes identified by PCLassoLog in the HCC dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>NO.</th><th>ID</th><th>Complex Name</th><th>Gene Symbol</th><th>SP<sup>a</sup></th><th>Reference<sup>c</sup></th></tr></thead><tbody><tr><td><bold>1</bold></td><td>2440</td><td>ITGA9-ITGB1-ADAM9 complex</td><td><bold>ITGB1</bold><sup>b</sup>; ADAM9; <bold>ITGA9</bold></td><td>1</td><td>ITGB1: 23441154; 28656629; 26509963; 26766915; 26903137; ITGA9: 31008533; 31489579; 26,596,831</td></tr><tr><td><bold>2</bold></td><td>7197</td><td>Methionine adenosyltransferase alpha1 beta-v1</td><td><bold>MAT1A</bold>; <bold>MAT2B</bold></td><td>1</td><td>MAT1A: 23665184; 32080887; 22318685; 31496615; 23241961; 24212770; MAT2B: 31493275; 31073374; 23814050; 18,698,677</td></tr><tr><td><bold>3</bold></td><td>7131</td><td>COMMD1-CCDC22-CCDC93-C16orf62 complex</td><td><bold>CCDC22</bold>; <bold>CCDC93</bold>; C16orf62; COMMD1</td><td>0.95</td><td>—</td></tr><tr><td><bold>4</bold></td><td>142</td><td>CD147-gamma-secretase complex</td><td><bold>BSG</bold>; PSEN1; NCSTN; <bold>APH1A</bold>; PSENEN</td><td>0.85</td><td>BSG: 31497203; 24264599; APH1A: 30,944,650</td></tr><tr><td><bold>5</bold></td><td>6998</td><td>ST3GAL6-EGFR complex</td><td><bold>EGFR</bold>; <bold>ST3GAL6</bold></td><td>0.81</td><td>EGFR: 24212818; 24318021; 25173978; ST3GAL6: 32929335; 25,061,176</td></tr><tr><td><bold>6</bold></td><td>3525</td><td>Tetrameric COG subcomplex</td><td><bold>COG7</bold>; COG8; <bold>COG5</bold>; COG6</td><td>0.77</td><td>—</td></tr><tr><td><bold>7</bold></td><td>519</td><td>AMY-1-S-AKAP84-RII-beta complex</td><td><bold>PRKAR2B</bold>; <bold>AKAP1</bold>; MYCBP</td><td>0.75</td><td>PRKAR2B: 29761841; 28008150; AKAP1: 28569781; 33193848; 33,868,472</td></tr><tr><td><bold>8</bold></td><td>7284</td><td>GSK3B-HSP90AA1-PKM2 complex</td><td><bold>HSP90AA1</bold>; PKM; <bold>GSK3B</bold></td><td>0.69</td><td>HSP90AA1: 20651736; 17513464; 34226297; 31567483; 30471108; GSK3B: 30144430; 32698955; 30,845,991</td></tr><tr><td><bold>9</bold></td><td>4158</td><td>HSP90-FKBP38-CAM-Ca (2 + ) complex</td><td><bold>HSP90AA1</bold>; CALM1; CAL; <bold>FKBP8</bold></td><td>0.68</td><td>HSP90AA1: 20651736; 17513464; 34226297; 31567483; 30471108; FKBP8: 30,348,988</td></tr><tr><td><bold>10</bold></td><td>6782</td><td>mitochondrial permeability transition pore (PTP) complex (PPIF-SPG7-VDAC1)</td><td><bold>VDAC1</bold>; <bold>PPIF</bold>; SPG7</td><td>0.67</td><td>23233904; 31364685; 22204343; 24781191; 29682501; 21315184; 23663973; 21297950; 27304056; PPIF: 33,495,413</td></tr></tbody></table><table-wrap-foot><fn><p>Shown are the top 10 risk protein complexes with the highest SP. The full list of risk protein complexes is provided in <bold>Table S10B</bold>. <sup>a</sup>Selection probability; <sup>b</sup>Proteins shown in bold are detected in the HCC datasets; <sup>c</sup>References related to the detected proteins in HCC or other cancer types.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0170">Among these 10 risk protein complexes, most of the detected proteins have been reported to play important roles in various cancer types (<xref rid="t0010" ref-type="table">Table 2</xref>). Some of these proteins are related to lung cancer. For example, in the MLC1-Na, K-ATPase-Kir4.1-AQP4-TRPV4-syntrophin complex, both ATP1B1 and AQP4 have been suggested as promising drug targets to combat non-small cell lung cancer <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>. Inhibiting ATP1B1 expression by siRNA or specific cardenolides treatment has been shown to result in markedly impaired proliferation and migration of lung cancer cells <xref rid="b0285" ref-type="bibr">[57]</xref>. Inhibiting AQP4 expression could significantly reduce lung cancer cell migration <xref rid="b0250" ref-type="bibr">[50]</xref>. Some proteins have been shown to be effective in inhibiting tumor proliferation, metastasis or promoting cell apoptosis by being targeted by drugs or miRNAs, such as GAPDH <xref rid="b0295" ref-type="bibr">[59]</xref> and PDIA3 <xref rid="b0300" ref-type="bibr">[60]</xref> in the HMGB1-HMGB2-HSC70-ERP60-GAPDH complex, and ITGB1 <xref rid="b0305" ref-type="bibr">[61]</xref> and JAM2 <xref rid="b0310" ref-type="bibr">[62]</xref> in the ITGA4-ITGB1-JAM2 complex. For HCC, the top 10 risk protein complexes also contain a large number of proteins related to the development of various cancer types (<xref rid="t0015" ref-type="table">Table 3</xref>). Some of these proteins have been shown to be targets of miRNAs or drugs and exert inhibitory effects in HCC, such as MAT1A <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, MAT2B <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref>, and AKAP1 <xref rid="b0340" ref-type="bibr">[68]</xref>. This indicates that the risk proteins identified by PCLassoLog have high credibility.</p>
      <p id="p0175">Among these risk proteins, a few proteins have been reported to form complexes with other proteins to play important functions in cancer. For example, the physical interaction between risk protein CAV1 and GLUT3 has been reported to be targeted by Atorvastatin to suppress tumor growth in non-small cell lung cancer <xref rid="b0090" ref-type="bibr">[18]</xref>. MAT2B has been reported to cross talk with HuR and SIRT1 to affect the pro-apoptotic and growth-suppressive effects of liver cancer <xref rid="b0335" ref-type="bibr">[67]</xref>. However, the role of interplay among the proteins contained in these risk protein complexes in cancer development remains largely unexplored. The risk protein complexes identified by PCLassoLog provide valuable targets for researchers to better study the synergistic effects of proteins at the protein complex level.</p>
    </sec>
    <sec id="s0095">
      <label>3.7</label>
      <title>Classification and risk protein complexes identification in pan-cancer</title>
      <p id="p0180">In view of the superior classification performance of PCLassoLog on LUAD and HCC, as well as the ability to identify risk protein complexes, we applied PCLassoLog to the classification and identification of risk protein complexes for 10 additional cancer types whose protein expression has been recently quantified <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref> (<xref rid="t0005" ref-type="table">Table 1</xref>). PCLassoLog achieved median AUC of 1, 1, 1, 0.987, 1, 0.989, 1, 1, 1, and 0.982 on the ccRCC, COAD, EC, ESCC, GBM, GC, HNSCC, LSCC, OV, and PDAC datasets, respectively (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>A and S17A-C</bold>). The risk protein complexes and their selection probabilities of the 10 cancer types are provided in <xref rid="s0135" ref-type="sec">Table S10</xref>.<fig id="f0025"><label>Fig. 5</label><caption><p>Pan-cancer analysis of risk protein complexes identified by PCLassoLog. (A) Box plots of AUCs of the PCLassoLog model on the protein expression data of 10 cancer types. For each cancer type, the entire dataset is randomly divided into a training set (2/3) and a test set (1/3). The training set is used to train the model, and the test set is used to evaluate the model. This process is repeated 100 times. Each boxplot represents 100 AUCs obtained on 100 test sets. (B) Risk protein complexes identified by the PCLassoLog model across multiple cancer types. Each row of the matrix represents a type of cancer, and each column represents a protein complex. The color of the (<italic>i</italic>, <italic>j</italic>) element of the matrix indicates the SP of the <italic>j</italic>-th protein complex identified as a risk protein complex of the <italic>i</italic>-th cancer type. The protein complex shown in red indicates that it is consistently up-regulated in the corresponding cancer types, while green indicates that it is consistently down-regulated. (C) The protein–protein network of risk protein complexes identified in multiple cancer types. The protein–protein interactions were obtained from the STRING database. The width of the line indicates the edge confidence. Pink nodes indicate that the proteins are consistently up-regulated in at least five cancer types, and cyan nodes indicate that the proteins are consistently down-regulated in at least five cancer types. The six consistently up-regulated protein complexes and one consistently down-regulated protein complexes marked in (B) are highlighted in red and green, respectively. HSP90 related complexes and cell cycle kinase complexes are highlighted in grey. (D) Risk protein complexes specific to each cancer type. The values in the rectangular boxes indicate selection probabilities. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr5"/></fig></p>
      <p id="p0185">Twenty-one protein complexes were identified as risk protein complexes in at least five cancer types (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>B</bold>). Some of these protein complexes contain well-known cancer-related proteins, such as HSP90-related protein complexes and cell cycle kinase complexes (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>C</bold>). Six protein complexes are consistently up-regulated (highlighted in red) in at least five cancer types, such as PLOD2-FKBP10 complex, SRSF9-SRSF6 complex, and FHL2-FHL3 complex (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>B-C</bold>). Only one protein complex, the Angiogenin-PRI complex, is consistently down-regulated (highlighted in green) in at least 5 caner types (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>B-C</bold>). These protein complexes that are consistently dysregulated in multiple cancer types may be valuable targets for revealing the molecular mechanism of cancers.</p>
      <p id="p0190">In contrast, some protein complexes were identified only in one cancer type. We define a protein complex that has a SP&gt;0.5 in one cancer type but is not identified in other cancer types as a risk protein complex specific to that cancer type. Eight protein complexes are specific to LUAD, such as CART complex and DNA repair complex (<xref rid="f0025" ref-type="fig">Fig. 5</xref><bold>D</bold>). The Methionine adenosyltransferase alpha1 beta-v1 complex is specific to HCC. Its member proteins MAT1A and MAT2B have been used as therapeutic targets for HCC drug development <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref>. Some of the proteins in these protein complexes have been suggested as biomarkers or therapeutic targets for the corresponding cancer type, such as PIK3C3 (Phosphatidylinositol 3-kinase complex) in GBM <xref rid="b0355" ref-type="bibr">[71]</xref>, and TGFBI (BP-SMAD complex) in GC <xref rid="b0360" ref-type="bibr">[72]</xref>. These cancer-specific protein complexes deserve further investigation.</p>
    </sec>
    <sec id="s0100">
      <label>3.8</label>
      <title>Comparison with survival-related risk protein complexes</title>
      <p id="p0195">We next compared the risk protein complexes identified by PCLassoLog and the survival-related risk protein complexes, which were identified by PCLasso <xref rid="b0095" ref-type="bibr">[19]</xref>. The main difference is that PCLassoLog uses class labels as dependent variables, while PCLasso uses survival outcomes. In other words, PCLassoLog identifies risk protein complexes on the premise of maximizing classification accuracy, while PCLasso is premised on maximizing prognostic accuracy. Therefore, the risk protein complexes identified by PCLassoLog may be mainly related to the initiation and development of cancer, while the risk protein complexes identified by PCLasso are more likely to be related to cancer progression.</p>
      <p id="p0200">A total of 10 cancer types were analyzed by both PCLassoLog and PCLasso. Only a few protein complexes are identified by both PCLassoLog and PCLasso in LUAD, HCC, ccRCC, EC, GC, HNSCC, and LSCC, respectively (<xref rid="s0135" ref-type="sec">Table S11</xref>). The risk protein complexes identified by the two models are very different in multiple cancer types, implying that the molecular mechanisms may also change at different stages of cancer development and progression. The common risk protein complexes identified by PCLasso and PCLassoLog may play a role in both cancer development and cancer progression. For example, the PLOD2-FKBP10 complex was identified by both PCLassoLog and PCLasso in LUAD (<xref rid="s0135" ref-type="sec">Table S11</xref>). PLOD2 has been shown to be elevated in NSCLC cells and related to poor prognosis in LUAD <xref rid="b0365" ref-type="bibr">[73]</xref>. It promotes NSCLC metastasis directly by enhancing migration and indirectly by inducing collagen reorganization <xref rid="b0365" ref-type="bibr">[73]</xref>. FKBP10 expression is also negatively correlated with the survival of lung cancer patients. FKBP10 downregulation has been shown to suppress lung cancer growth and cancer stem-like features <xref rid="b0370" ref-type="bibr">[74]</xref>. Two integrin complexes (ITGAV-ITGB1 complex and ITGB1-NRP1 complex) were identified by both PCLassoLog and PCLasso in GC (<xref rid="s0135" ref-type="sec">Table S11</xref>). The integrin family regulates a diverse array of cellular functions crucial to the initiation, progression, and metastasis of solid tumours <xref rid="b0375" ref-type="bibr">[75]</xref>. ITGAV has been shown to be overexpressed in GC and associated with shorter overall survival and disease-free survival. Downregulation of ITGAV could result in suppression of proliferation, migration, and invasion of GC cells <xref rid="b0380" ref-type="bibr">[76]</xref>. ITGB1 has been shown to be targeted by miR-29c to mediate GC initiation <xref rid="b0385" ref-type="bibr">[77]</xref> and targeted by miR-29a to mediate GC metastasis <xref rid="b0390" ref-type="bibr">[78]</xref>. The importance of integrins that affect nearly every step of cancer progression from primary tumour development to metastasis has made them an appealing target for cancer therapy <xref rid="b0375" ref-type="bibr">[75]</xref>, <xref rid="b0395" ref-type="bibr">[79]</xref>. The risk protein complexes identified by PCLassoLog and PCLasso are both important, and they could complement each other to reveal the molecular mechanism of different stages of cancer from a more comprehensive perspective.</p>
    </sec>
    <sec id="s0105">
      <label>3.9</label>
      <title>Risk protein complexes associated with genomic mutations in LUAD</title>
      <p id="p0205">In addition to risk protein complexes related to cancer development, PCLassoLog can also be used to identify risk protein complexes in other contexts, such as risk protein complex related to genomic mutations. Based on protein expression data from the studies of Gillette et al. <xref rid="b0100" ref-type="bibr">[20]</xref>, we applied PCLassoLog to classification of LUAD patients with/without TP53, KRAS, STK11, EGFR, KEAP1, RB1, BRAF mutation, and ALK fusion, and obtained median AUC of 0.844, 0.675, 0.862, 0.780, 0.947, 0.686, 0.843, and 0.985, respectively (<xref rid="s0135" ref-type="sec">Figure S18</xref>). This indicates that protein complexes could accurately predict some mutant phenotypes in LUAD, especially TP53, STK11, KEAP1 mutation, and ALK fusion. Risk protein complexes related to each mutant phenotype were identified (<xref rid="s0135" ref-type="sec">Table S12</xref>). Among them, risk protein complexes with the largest SP include the sulphiredoxin-peroxiredoxin complex (SP = 1) that related to KEAP1 mutation, the DDX11-Ctf18-RFC complex (SP = 0.99) and MDC1-H2AFX-TP53BP1 complex (SP = 0.92) that related to TP53 mutation, the RhBG-kAE1-ankyrin-G complex (SP = 0.83) that related to ALK fusion.</p>
    </sec>
  </sec>
  <sec id="s0110">
    <label>4</label>
    <title>Discussion</title>
    <p id="p0210">In this study, we propose the PCLassoLog model and verify its high classification accuracy and ability to identify reliable risk protein complexes. Using PCLassoLog, we identified risk protein complexes associated with cancer development in 12 cancer types and with gene mutations in LUAD. Pan-cancer analysis revealed risk protein complexes that play important functions in multiple cancer types and risk protein complexes specific to each cancer type.</p>
    <p id="p0215">PCLassoLog embeds protein complexes into the group Lasso-logistic model, and uses mixed <italic>l</italic><sub>1</sub> and <italic>l</italic><sub>2</sub> penalties to achieve feature selection. At the individual protein level of each protein complex, the <italic>l</italic><sub>2</sub> norm fits the regression coefficients to obtain the optimal linear combination to accumulate the weaker discriminant ability of individual proteins and form pseudo-proteins at the protein complex level with strong discriminant ability. The <italic>l</italic><sub>1</sub> penalty tends to choose only a few nonzero coefficients. Thus, at the protein complex level, the <italic>l</italic><sub>1</sub> norm ensures selection of a few important protein complexes, which are referred to as risk protein complexes. By introducing latent variables, PCLassoLog can elegantly handle the overlap problem of protein complexes. Although many proteins are subunits of more than one protein complex, PCLassoLog produces a sparse solution, which matches the way proteins function in different protein complexes. For a protein belonging to multiple protein complexes, PCLassoLog independently estimates its regression coefficient in different protein complexes. The coefficients of this protein in the unselected protein complexes will be zero. In contrast, the coefficients of this protein in the selected protein complexes will be nonzero and will contribute to the final model. This is consistent with that a protein may belong to multiple protein complexes, but only some of them are related to the development of cancer.</p>
    <p id="p0220">Compared with the Lasso-logistic model based on individual proteins, PCLassoLog selects features with stronger reproducibility at the level of protein complexes across different datasets (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>D</bold>). In terms of classification accuracy, although the prediction performance of the Lasso-logistic model on the test sets is comparable to that of PCLassoLog, its prediction performance on the independent datasets decreases dramatically (<xref rid="f0020" ref-type="fig">Fig. 4</xref><bold>A-C</bold>). This may be due to the unstable expression of individual proteins, which is usually caused by tumor heterogeneity or batch effects <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref>. Protein complexes have been reported to be inherently resistant to batch effects and have the advantage of being more robust than individual proteins as features at the functional level <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0405" ref-type="bibr">[81]</xref>. Thus, it is not surprising that PCLassoLog can achieve more robust prediction performance on independent datasets. Both models use cross-validation to select the optimal <italic>λ</italic>. Accordingly, the Lasso-logistic model included less proteins than PCLassoLog (<xref rid="s0135" ref-type="sec">Figure S7</xref>). We also investigated a variant of Lasso-logistic model (Lasso-logistic2) which selects the same number of features as PCLassoLog by controlling <italic>λ</italic> (<xref rid="s0135" ref-type="sec">Figure S19</xref><bold>A</bold>). The prediction performance of the Lasso-logistic2 model is comparable to that of the Lasso-logistic model on the test set, but poor on the independent data sets (<xref rid="s0135" ref-type="sec">Figure S19</xref><bold>B-C</bold>). This further indicates that PCLassoLog has a more robust and accurate performance when the number of protein features is comparable. Compared with the Lasso-logistic model with elastic net penalty (ENet, <italic>α</italic> = 0.5), which also uses both <italic>l</italic><sub>1</sub> and <italic>l</italic><sub>2</sub> penalties, the predictive performance of PCLassoLog was better in the “LUAD.Gillette.Prot” case and slightly worse in the “LUAD.Xu.Prot” and “HCC” case. However, PCLassoLog has the characteristic of identifying risk protein complexes that ENet does not have. In addition, although PCLassoLog is a linear model, the overall predictive performance is better than that of nonlinear models such as random forest and extreme gradient boosting (see <bold>Supplementary Text</bold> for details) in the three cases (<xref rid="s0135" ref-type="sec">Figure S20</xref>).</p>
    <p id="p0225">Compared with PCSCAD and PCMCP, PCLassoLog has the highest prediction accuracy on independent datasets (<xref rid="s0135" ref-type="sec">Figure S8-</xref><bold>10</bold>), which could be attributed to it recruiting more protein complexes into the model in order to compensate for its over-shrinkage of large coefficients. However, this may also cause PCLassoLog to include some irrelevant features into the model. Therefore, we calculated the selection probability of each risk protein complex to measure its reliability. In general, it is reliable enough to select risk protein complexes with a probability&gt;0.5 <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref>. In addition, PCSCAD and PCMCP are implemented to complement PCLassoLog in identifying reliable risk protein complexes. PCSCAD and PCMCP effectively capture important features by reducing the penalty for large coefficients, but at the expense of certain prediction accuracy. The three models could be used in combination to better complete the task of accurate classification and identifying risk protein complexes. Nonetheless, because there is no gold standard for risk protein complexes at present, we cannot use a precision and recall framework to evaluate the reliability of the risk protein complexes discovered, which will be an issue to be further resolved in the future.</p>
    <p id="p0230">Similar to the PCLasso model, the most important contribution of PCLassoLog is the ability to identify risk protein complexes, which may provide valuable targets for researchers to study the synergistic effects of proteins on cancer development. The difference is that PCLasso identifies risk protein complexes associated with cancer progression, whereas PCLassoLog identifies risk protein complexes associated with cancer initiation and development. Moreover, PCLassoLog can be used to identify risk protein complexes in other contexts, such as those associated with genomic mutation (<xref rid="s0135" ref-type="sec">Table S12</xref>). With risk protein complexes, researchers can discover and understand protein functions and carcinogenic mechanisms from a more comprehensive perspective. Further, new therapeutic strategies could be developed from the perspective of the complex, such as simultaneously inhibiting the expression of proteins in the complex, or blocking their binding, etc. PCLassoLog provides researchers with an effective tool to discover unknown risk protein complexes. Note that one limit of PCLassoLog is that the risk protein complexes identified by PCLassoLog are derived from the known protein complex database CORUM. Since changes in protein interactions during cancer progression may form new protein complexes that play key carcinogenic roles, how to identify such dynamic risk protein complexes is an issue worthy of further research.</p>
    <p id="p0235">We have developed an R package ‘PCLassoReg’ (<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=PCLassoReg" id="ir010">https://CRAN.R-project.org/package=PCLassoReg</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://github.com/weiliu123/PCLassoReg" id="ir015">https://github.com/weiliu123/PCLassoReg</ext-link>), a freely available implementation of all protein complex-based models, including PCLassoLog, PCSCAD, PCMCP, and PCLasso. In addition to the risk protein complexes discovered in this study (<xref rid="s0135" ref-type="sec">Table S10 and S12</xref>), researchers can use our package to identify risk protein complexes for other cancer types or in other contexts based on their own data.</p>
  </sec>
  <sec id="s0115">
    <label>5</label>
    <title>Availability</title>
    <p id="p0240">PCLassoLog is an R package freely available in CRAN (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=PCLassoReg" id="ir020"><underline>https://CRAN.R-project.org/package=PCLassoReg</underline></ext-link>) and the GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/weiliu123/PCLassoReg" id="ir025"><underline>https://github.com/weiliu123/PCLassoReg</underline></ext-link>).</p>
  </sec>
  <sec id="s0120">
    <title>Funding</title>
    <p id="p0245">This work was supported by the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> [82272945; 11901170], the Natural Science Foundation of Heilongjiang Province [LH2021F048], the National Fund cultivation special project [2021GJ09], and the Provincial Echelon Training Program of Heilongjiang Institute of Technology [2020LJ01].</p>
  </sec>
  <sec id="s0125">
    <title>CRediT authorship contribution statement</title>
    <p id="p0250"><bold>Wei Wang:</bold> Methodology, Software, Writing – original draft. <bold>Haiyan Yuan:</bold> Visualization, Investigation. <bold>Junwei Han:</bold> Conceptualization. <bold>Wei Liu:</bold> Conceptualization, Methodology, Software, Writing – review &amp; editing.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0255">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>López-Bigas</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Ouzounis</surname>
            <given-names>C.A.</given-names>
          </name>
        </person-group>
        <article-title>Genome-wide identification of genes likely to be involved in human genetic disease</article-title>
        <source>Nucleic Acids Res</source>
        <volume>32</volume>
        <year>2004</year>
        <fpage>3108</fpage>
        <lpage>3114</lpage>
        <pub-id pub-id-type="pmid">15181176</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Köhler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Horn</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Walking the interactome for prioritization of candidate disease genes</article-title>
        <source>Am J Hum Genet</source>
        <volume>82</volume>
        <year>2008</year>
        <fpage>949</fpage>
        <lpage>958</lpage>
        <pub-id pub-id-type="pmid">18371930</pub-id>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Smedley</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Köhler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Czeschik</surname>
            <given-names>J.C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Walking the interactome for candidate prioritization in exome sequencing studies of Mendelian diseases</article-title>
        <source>Bioinformatics</source>
        <volume>30</volume>
        <year>2014</year>
        <fpage>3215</fpage>
        <lpage>3222</lpage>
        <pub-id pub-id-type="pmid">25078397</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Gambin</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Bi</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of novel candidate disease genes from de novo exonic copy number variants</article-title>
        <source>Genome Med</source>
        <volume>9</volume>
        <year>2017</year>
        <fpage>83</fpage>
        <pub-id pub-id-type="pmid">28934986</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Ang</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Mirzal</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Haron</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Supervised, Unsupervised, and Semi-Supervised Feature Selection: A Review on Gene Selection</article-title>
        <source>IEEE/ACM Trans Comput Biol Bioinf</source>
        <volume>13</volume>
        <year>2016</year>
        <fpage>971</fpage>
        <lpage>989</lpage>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>Lazar</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Taminau</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Meganck</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A survey on filter techniques for feature selection in gene expression microarray analysis</article-title>
        <source>IEEE/ACM Trans Comput Biol Bioinform</source>
        <volume>9</volume>
        <year>2012</year>
        <fpage>1106</fpage>
        <lpage>1119</lpage>
        <pub-id pub-id-type="pmid">22350210</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Giurgiu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Reinhard</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Brauner</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CORUM: the comprehensive resource of mammalian protein complexes-2019</article-title>
        <source>Nucleic Acids Res</source>
        <volume>47</volume>
        <year>2019</year>
        <fpage>D559</fpage>
        <lpage>D563</lpage>
        <pub-id pub-id-type="pmid">30357367</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Güldener</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Münsterkötter</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kastenmüller</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CYGD: the Comprehensive Yeast Genome Database</article-title>
        <source>Nucleic Acids Res</source>
        <volume>33</volume>
        <year>2005</year>
        <fpage>D364</fpage>
        <lpage>D368</lpage>
        <pub-id pub-id-type="pmid">15608217</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Berggård</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Linse</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Methods for the detection and analysis of protein-protein interactions</article-title>
        <source>Proteomics</source>
        <volume>7</volume>
        <year>2007</year>
        <fpage>2833</fpage>
        <lpage>2842</lpage>
        <pub-id pub-id-type="pmid">17640003</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Ruepp</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Brauner</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Dunger-Kaltenbach</surname>
            <given-names>I.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CORUM: the comprehensive resource of mammalian protein complexes</article-title>
        <source>Nucleic Acids Res</source>
        <volume>36</volume>
        <year>2008</year>
        <fpage>D646</fpage>
        <lpage>D650</lpage>
        <pub-id pub-id-type="pmid">17965090</pub-id>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mass Spectrometry-Based Protein Complex Profiling in Time and Space</article-title>
        <source>Anal Chem</source>
        <volume>93</volume>
        <year>2021</year>
        <fpage>598</fpage>
        <lpage>619</lpage>
        <pub-id pub-id-type="pmid">33146515</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Bludau</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Proteomic and interactomic insights into the molecular basis of cell functional diversity</article-title>
        <source>Nat Rev Mol Cell Biol</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>327</fpage>
        <lpage>340</lpage>
        <pub-id pub-id-type="pmid">32235894</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Jang</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Bouhaddou</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>
        <source>Nature</source>
        <volume>583</volume>
        <year>2020</year>
        <fpage>459</fpage>
        <lpage>468</lpage>
        <pub-id pub-id-type="pmid">32353859</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Nollet</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Berx</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>van Roy</surname>
            <given-names>F.</given-names>
          </name>
        </person-group>
        <article-title>The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer</article-title>
        <source>Mol Cell Biol Res Commun</source>
        <volume>2</volume>
        <year>1999</year>
        <fpage>77</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="pmid">10542129</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>Fu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>T.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis</article-title>
        <source>Cell Res</source>
        <volume>21</volume>
        <year>2011</year>
        <fpage>275</fpage>
        <lpage>289</lpage>
        <pub-id pub-id-type="pmid">20714342</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Lepourcelet</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.N.</given-names>
          </name>
          <name>
            <surname>France</surname>
            <given-names>D.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex</article-title>
        <source>Cancer Cell</source>
        <volume>5</volume>
        <year>2004</year>
        <fpage>91</fpage>
        <lpage>102</lpage>
        <pub-id pub-id-type="pmid">14749129</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <mixed-citation publication-type="other" id="h0085">Luo Z, Liu W, Sun P et al. Pan-cancer analyses reveal regulation and clinical outcome association of the shelterin complex in cancer, <italic>Brief Bioinform</italic> 2021;22:bbaa441.</mixed-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Ali</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Levantini</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Fhu</surname>
            <given-names>C.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer</article-title>
        <source>Theranostics</source>
        <volume>9</volume>
        <year>2019</year>
        <fpage>6157</fpage>
        <lpage>6174</lpage>
        <pub-id pub-id-type="pmid">31534543</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <mixed-citation publication-type="other" id="h0095">Wang W, Liu W. PCLasso: a protein complex-based, group lasso-Cox model for accurate prognosis and risk protein complex discovery, <italic>Brief Bioinform</italic> 2021;22:bbab212.</mixed-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Satpathy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma</article-title>
        <source>Cell</source>
        <volume>182</volume>
        <year>2020</year>
        <fpage>200</fpage>
        <lpage>225.e235</lpage>
        <pub-id pub-id-type="pmid">32649874</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrative Proteomic Characterization of Human Lung Adenocarcinoma</article-title>
        <source>Cell</source>
        <volume>182</volume>
        <year>2020</year>
        <fpage>245</fpage>
        <lpage>261.e217</lpage>
        <pub-id pub-id-type="pmid">32649877</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma</article-title>
        <source>Cell</source>
        <volume>179</volume>
        <year>2019</year>
        <fpage>561</fpage>
        <lpage>577.e522</lpage>
        <pub-id pub-id-type="pmid">31585088</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Clark</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Dhanasekaran</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma</article-title>
        <source>Cell</source>
        <volume>179</volume>
        <year>2019</year>
        <fpage>964</fpage>
        <lpage>983.e931</lpage>
        <pub-id pub-id-type="pmid">31675502</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Vasaikar</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities</article-title>
        <source>Cell</source>
        <volume>177</volume>
        <year>2019</year>
        <fpage>1035</fpage>
        <lpage>1049.e1019</lpage>
        <pub-id pub-id-type="pmid">31031003</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Dou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Kawaler</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization of Endometrial Carcinoma</article-title>
        <source>Cell</source>
        <volume>180</volume>
        <year>2020</year>
        <fpage>729</fpage>
        <lpage>748.e726</lpage>
        <pub-id pub-id-type="pmid">32059776</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>26</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Y.H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting</article-title>
        <source>Nat Commun</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>4961</fpage>
        <pub-id pub-id-type="pmid">34400640</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>27</label>
      <element-citation publication-type="journal" id="h0135">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>L.B.</given-names>
          </name>
          <name>
            <surname>Karpova</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>M.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic and metabolomic characterization of human glioblastoma</article-title>
        <source>Cancer Cell</source>
        <volume>39</volume>
        <year>2021</year>
        <fpage>509</fpage>
        <lpage>528.e520</lpage>
        <pub-id pub-id-type="pmid">33577785</pub-id>
      </element-citation>
    </ref>
    <ref id="b0140">
      <label>28</label>
      <element-citation publication-type="journal" id="h0140">
        <person-group person-group-type="author">
          <name>
            <surname>Ge</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A proteomic landscape of diffuse-type gastric cancer</article-title>
        <source>Nat Commun</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>1012</fpage>
        <pub-id pub-id-type="pmid">29520031</pub-id>
      </element-citation>
    </ref>
    <ref id="b0145">
      <label>29</label>
      <element-citation publication-type="journal" id="h0145">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>S.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma</article-title>
        <source>Cancer Cell</source>
        <volume>39</volume>
        <year>2021</year>
        <fpage>361</fpage>
        <lpage>379.e316</lpage>
        <pub-id pub-id-type="pmid">33417831</pub-id>
      </element-citation>
    </ref>
    <ref id="b0150">
      <label>30</label>
      <element-citation publication-type="journal" id="h0150">
        <person-group person-group-type="author">
          <name>
            <surname>Satpathy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Krug</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Jean Beltran</surname>
            <given-names>P.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A proteogenomic portrait of lung squamous cell carcinoma</article-title>
        <source>Cell</source>
        <volume>184</volume>
        <year>2021</year>
        <fpage>4348</fpage>
        <lpage>4371.e4340</lpage>
        <pub-id pub-id-type="pmid">34358469</pub-id>
      </element-citation>
    </ref>
    <ref id="b0155">
      <label>31</label>
      <element-citation publication-type="journal" id="h0155">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma</article-title>
        <source>Cell Rep</source>
        <volume>33</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">108276</object-id>
      </element-citation>
    </ref>
    <ref id="b0160">
      <label>32</label>
      <element-citation publication-type="journal" id="h0160">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic characterization of pancreatic ductal adenocarcinoma</article-title>
        <source>Cell</source>
        <volume>184</volume>
        <year>2021</year>
        <fpage>5031</fpage>
        <lpage>5052.e5026</lpage>
        <pub-id pub-id-type="pmid">34534465</pub-id>
      </element-citation>
    </ref>
    <ref id="b0165">
      <label>33</label>
      <element-citation publication-type="journal" id="h0165">
        <person-group person-group-type="author">
          <name>
            <surname>Landi</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Dracheva</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Rotunno</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival</article-title>
        <source>PLoS One</source>
        <volume>3</volume>
        <year>2008</year>
        <fpage>e1651</fpage>
        <pub-id pub-id-type="pmid">18297132</pub-id>
      </element-citation>
    </ref>
    <ref id="b0170">
      <label>34</label>
      <element-citation publication-type="journal" id="h0170">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Tsai</surname>
            <given-names>M.H.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women</article-title>
        <source>Cancer Epidemiol Biomarkers Prev</source>
        <volume>19</volume>
        <year>2010</year>
        <fpage>2590</fpage>
        <lpage>2597</lpage>
        <pub-id pub-id-type="pmid">20802022</pub-id>
      </element-citation>
    </ref>
    <ref id="b0175">
      <label>35</label>
      <element-citation publication-type="journal" id="h0175">
        <person-group person-group-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Aerts</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>den Hamer</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression-based classification of non-small cell lung carcinomas and survival prediction</article-title>
        <source>PLoS One</source>
        <volume>5</volume>
        <year>2010</year>
        <fpage>e10312</fpage>
        <pub-id pub-id-type="pmid">20421987</pub-id>
      </element-citation>
    </ref>
    <ref id="b0180">
      <label>36</label>
      <element-citation publication-type="journal" id="h0180">
        <person-group person-group-type="author">
          <name>
            <surname>Villa</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Critelli</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study</article-title>
        <source>Gut</source>
        <volume>65</volume>
        <year>2016</year>
        <fpage>861</fpage>
        <lpage>869</lpage>
        <pub-id pub-id-type="pmid">25666192</pub-id>
      </element-citation>
    </ref>
    <ref id="b0185">
      <label>37</label>
      <element-citation publication-type="journal" id="h0185">
        <person-group person-group-type="author">
          <name>
            <surname>Grinchuk</surname>
            <given-names>O.V.</given-names>
          </name>
          <name>
            <surname>Yenamandra</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Iyer</surname>
            <given-names>R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma</article-title>
        <source>Mol Oncol</source>
        <volume>12</volume>
        <year>2018</year>
        <fpage>89</fpage>
        <lpage>113</lpage>
        <pub-id pub-id-type="pmid">29117471</pub-id>
      </element-citation>
    </ref>
    <ref id="b0190">
      <label>38</label>
      <element-citation publication-type="journal" id="h0190">
        <person-group person-group-type="author">
          <name>
            <surname>Makowska</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Boldanova</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Adametz</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma</article-title>
        <source>J Pathol Clin Res</source>
        <volume>2</volume>
        <year>2016</year>
        <fpage>80</fpage>
        <lpage>92</lpage>
        <pub-id pub-id-type="pmid">27499918</pub-id>
      </element-citation>
    </ref>
    <ref id="b0195">
      <label>39</label>
      <element-citation publication-type="journal" id="h0195">
        <person-group person-group-type="author">
          <name>
            <surname>Roessler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>H.L.</given-names>
          </name>
          <name>
            <surname>Budhu</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients</article-title>
        <source>Cancer Res</source>
        <volume>70</volume>
        <year>2010</year>
        <fpage>10202</fpage>
        <lpage>10212</lpage>
        <pub-id pub-id-type="pmid">21159642</pub-id>
      </element-citation>
    </ref>
    <ref id="b0200">
      <label>40</label>
      <element-citation publication-type="journal" id="h0200">
        <person-group person-group-type="author">
          <name>
            <surname>Ming</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yi</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Model selection and estimation in regression with grouped variables</article-title>
        <source>J R Stat Soc Ser B (Stat Methodol)</source>
        <volume>68</volume>
        <year>2006</year>
        <fpage>49</fpage>
        <lpage>67</lpage>
      </element-citation>
    </ref>
    <ref id="b0205">
      <label>41</label>
      <mixed-citation publication-type="other" id="h0205">Jacob L, Obozinski G, Vert JP. Group lasso with overlap and graph lasso. In International Conference on Machine Learning. 2009.</mixed-citation>
    </ref>
    <ref id="b0210">
      <label>42</label>
      <element-citation publication-type="journal" id="h0210">
        <person-group person-group-type="author">
          <name>
            <surname>Park</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Niida</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Miyano</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sparse overlapping group lasso for integrative multi-omics analysis</article-title>
        <source>J Comput Biol</source>
        <volume>22</volume>
        <year>2015</year>
        <fpage>73</fpage>
        <lpage>84</lpage>
        <pub-id pub-id-type="pmid">25629319</pub-id>
      </element-citation>
    </ref>
    <ref id="b0215">
      <label>43</label>
      <element-citation publication-type="journal" id="h0215">
        <person-group person-group-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>J.Q.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R.Z.</given-names>
          </name>
        </person-group>
        <article-title>Variable Selection via Nonconcave Penalized Likelihood and its Oracle Properties</article-title>
        <source>Publ Am Stat Assoc</source>
        <volume>96</volume>
        <year>2001</year>
        <fpage>1348</fpage>
        <lpage>1360</lpage>
      </element-citation>
    </ref>
    <ref id="b0220">
      <label>44</label>
      <element-citation publication-type="journal" id="h0220">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>C.H.</given-names>
          </name>
        </person-group>
        <article-title>Nearly unbiased variable selection under minimax concave penalty</article-title>
        <source>Ann Stat</source>
        <volume>38</volume>
        <year>2010</year>
        <fpage>894</fpage>
        <lpage>942</lpage>
      </element-citation>
    </ref>
    <ref id="b0225">
      <label>45</label>
      <element-citation publication-type="journal" id="h0225">
        <person-group person-group-type="author">
          <name>
            <surname>Alexander</surname>
            <given-names>D.H.</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Stability selection for genome-wide association</article-title>
        <source>Genet Epidemiol</source>
        <volume>35</volume>
        <year>2011</year>
        <fpage>722</fpage>
        <lpage>728</lpage>
        <pub-id pub-id-type="pmid">22009793</pub-id>
      </element-citation>
    </ref>
    <ref id="b0230">
      <label>46</label>
      <element-citation publication-type="journal" id="h0230">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Penalized logistic regression for high-dimensional DNA methylation data with case-control studies</article-title>
        <source>Bioinformatics</source>
        <volume>28</volume>
        <year>2012</year>
        <fpage>1368</fpage>
        <lpage>1375</lpage>
        <pub-id pub-id-type="pmid">22467913</pub-id>
      </element-citation>
    </ref>
    <ref id="b0235">
      <label>47</label>
      <element-citation publication-type="journal" id="h0235">
        <person-group person-group-type="author">
          <name>
            <surname>Meinshausen</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Bühlmann</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Stability selection</article-title>
        <source>J R Stat Soc</source>
        <volume>72</volume>
        <year>2010</year>
        <fpage>417</fpage>
        <lpage>473</lpage>
      </element-citation>
    </ref>
    <ref id="b0240">
      <label>48</label>
      <element-citation publication-type="journal" id="h0240">
        <person-group person-group-type="author">
          <name>
            <surname>Nikou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Arbi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dimitrakopoulos</surname>
            <given-names>F.-I.-D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival</article-title>
        <source>J Mol Histol</source>
        <volume>51</volume>
        <year>2020</year>
        <fpage>385</fpage>
        <lpage>400</lpage>
        <pub-id pub-id-type="pmid">32592097</pub-id>
      </element-citation>
    </ref>
    <ref id="b0245">
      <label>49</label>
      <element-citation publication-type="journal" id="h0245">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>A.H.</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>W.H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PARVA promotes metastasis by modulating ILK signalling pathway in lung adenocarcinoma</article-title>
        <source>PLoS One</source>
        <volume>10</volume>
        <year>2015</year>
        <fpage>e0118530</fpage>
        <pub-id pub-id-type="pmid">25738875</pub-id>
      </element-citation>
    </ref>
    <ref id="b0250">
      <label>50</label>
      <element-citation publication-type="journal" id="h0250">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Aquaporin 1 and aquaporin 4 are involved in invasion of lung cancer cells</article-title>
        <source>Clin Lab</source>
        <volume>58</volume>
        <year>2012</year>
        <fpage>75</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="pmid">22372348</pub-id>
      </element-citation>
    </ref>
    <ref id="b0255">
      <label>51</label>
      <element-citation publication-type="journal" id="h0255">
        <person-group person-group-type="author">
          <name>
            <surname>Regala</surname>
            <given-names>R.P.</given-names>
          </name>
          <name>
            <surname>Weems</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Jamieson</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity</article-title>
        <source>J Biol Chem</source>
        <volume>280</volume>
        <year>2005</year>
        <fpage>31109</fpage>
        <lpage>31115</lpage>
        <pub-id pub-id-type="pmid">15994303</pub-id>
      </element-citation>
    </ref>
    <ref id="b0260">
      <label>52</label>
      <element-citation publication-type="journal" id="h0260">
        <person-group person-group-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway</article-title>
        <source>J Clin Invest</source>
        <volume>119</volume>
        <year>2009</year>
        <fpage>349</fpage>
        <lpage>361</lpage>
        <pub-id pub-id-type="pmid">19139564</pub-id>
      </element-citation>
    </ref>
    <ref id="b0265">
      <label>53</label>
      <element-citation publication-type="journal" id="h0265">
        <person-group person-group-type="author">
          <name>
            <surname>Kleiber</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Strebhardt</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>B.T.</given-names>
          </name>
        </person-group>
        <article-title>The biological relevance of FHL2 in tumour cells and its role as a putative cancer target</article-title>
        <source>Anticancer Res</source>
        <volume>27</volume>
        <year>2007</year>
        <fpage>55</fpage>
        <lpage>61</lpage>
        <pub-id pub-id-type="pmid">17352216</pub-id>
      </element-citation>
    </ref>
    <ref id="b0270">
      <label>54</label>
      <element-citation publication-type="journal" id="h0270">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>H.H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis</article-title>
        <source>Gastroenterology</source>
        <volume>132</volume>
        <year>2007</year>
        <fpage>1066</fpage>
        <lpage>1076</lpage>
        <pub-id pub-id-type="pmid">17383428</pub-id>
      </element-citation>
    </ref>
    <ref id="b0275">
      <label>55</label>
      <element-citation publication-type="journal" id="h0275">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ng</surname>
            <given-names>S.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities</article-title>
        <source>Glia</source>
        <volume>56</volume>
        <year>2008</year>
        <fpage>1328</fpage>
        <lpage>1338</lpage>
        <pub-id pub-id-type="pmid">18615633</pub-id>
      </element-citation>
    </ref>
    <ref id="b0280">
      <label>56</label>
      <element-citation publication-type="journal" id="h0280">
        <person-group person-group-type="author">
          <name>
            <surname>Niu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Downregulation and antiproliferative role of FHL3 in breast cancer</article-title>
        <source>IUBMB Life</source>
        <volume>63</volume>
        <year>2011</year>
        <fpage>764</fpage>
        <lpage>771</lpage>
        <pub-id pub-id-type="pmid">22362714</pub-id>
      </element-citation>
    </ref>
    <ref id="b0285">
      <label>57</label>
      <element-citation publication-type="journal" id="h0285">
        <person-group person-group-type="author">
          <name>
            <surname>Mijatovic</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Roland</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Van Quaquebeke</surname>
            <given-names>E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers</article-title>
        <source>J Pathol</source>
        <volume>212</volume>
        <year>2007</year>
        <fpage>170</fpage>
        <lpage>179</lpage>
        <pub-id pub-id-type="pmid">17471453</pub-id>
      </element-citation>
    </ref>
    <ref id="b0290">
      <label>58</label>
      <element-citation publication-type="journal" id="h0290">
        <person-group person-group-type="author">
          <name>
            <surname>Warth</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Muley</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Meister</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Loss of aquaporin-4 expression and putative function in non-small cell lung cancer</article-title>
        <source>BMC Cancer</source>
        <volume>11</volume>
        <year>2011</year>
        <fpage>161</fpage>
        <pub-id pub-id-type="pmid">21548930</pub-id>
      </element-citation>
    </ref>
    <ref id="b0295">
      <label>59</label>
      <element-citation publication-type="journal" id="h0295">
        <person-group person-group-type="author">
          <name>
            <surname>Yun</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mullarky</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH</article-title>
        <source>Science</source>
        <volume>350</volume>
        <year>2015</year>
        <fpage>1391</fpage>
        <lpage>1396</lpage>
        <pub-id pub-id-type="pmid">26541605</pub-id>
      </element-citation>
    </ref>
    <ref id="b0300">
      <label>60</label>
      <element-citation publication-type="journal" id="h0300">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3</article-title>
        <source>Mol Med Rep</source>
        <volume>12</volume>
        <year>2015</year>
        <fpage>3923</fpage>
        <lpage>3929</lpage>
        <pub-id pub-id-type="pmid">26004124</pub-id>
      </element-citation>
    </ref>
    <ref id="b0305">
      <label>61</label>
      <mixed-citation publication-type="other" id="h0305">Laudato S, Patil N, Abba ML et al. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1 2017;141:1879-1890.</mixed-citation>
    </ref>
    <ref id="b0310">
      <label>62</label>
      <mixed-citation publication-type="other" id="h0310">Li GC, Cao XY, Li YN et al. MicroRNA-374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2 2018;233:7379-7390.</mixed-citation>
    </ref>
    <ref id="b0315">
      <label>63</label>
      <element-citation publication-type="journal" id="h0315">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>T.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma</article-title>
        <source>J Clin Invest</source>
        <volume>123</volume>
        <year>2013</year>
        <fpage>285</fpage>
        <lpage>298</lpage>
        <pub-id pub-id-type="pmid">23241961</pub-id>
      </element-citation>
    </ref>
    <ref id="b0320">
      <label>64</label>
      <element-citation publication-type="journal" id="h0320">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Reciprocal Regulation Between Forkhead Box M1/NF-κB and Methionine Adenosyltransferase 1A Drives Liver Cancer</article-title>
        <source>Hepatology</source>
        <volume>72</volume>
        <year>2020</year>
        <fpage>1682</fpage>
        <lpage>1700</lpage>
        <pub-id pub-id-type="pmid">32080887</pub-id>
      </element-citation>
    </ref>
    <ref id="b0325">
      <label>65</label>
      <element-citation publication-type="journal" id="h0325">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Ying</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma</article-title>
        <source>Clin Exp Med</source>
        <volume>19</volume>
        <year>2019</year>
        <fpage>535</fpage>
        <lpage>546</lpage>
        <pub-id pub-id-type="pmid">31493275</pub-id>
      </element-citation>
    </ref>
    <ref id="b0330">
      <label>66</label>
      <element-citation publication-type="journal" id="h0330">
        <person-group person-group-type="author">
          <name>
            <surname>Simile</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Peitta</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Tomasi</surname>
            <given-names>M.L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes</article-title>
        <source>Oncotarget</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>2835</fpage>
        <lpage>2854</lpage>
        <pub-id pub-id-type="pmid">31073374</pub-id>
      </element-citation>
    </ref>
    <ref id="b0335">
      <label>67</label>
      <element-citation publication-type="journal" id="h0335">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>T.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Methionine adenosyltransferase 2B, HuR, and sirtuin 1 protein cross-talk impacts on the effect of resveratrol on apoptosis and growth in liver cancer cells</article-title>
        <source>J Biol Chem</source>
        <volume>288</volume>
        <year>2013</year>
        <fpage>23161</fpage>
        <lpage>23170</lpage>
        <pub-id pub-id-type="pmid">23814050</pub-id>
      </element-citation>
    </ref>
    <ref id="b0340">
      <label>68</label>
      <element-citation publication-type="journal" id="h0340">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hypoxia-induced circular RNA hsa_circ_0008450 accelerates hepatocellular cancer progression via the miR-431/AKAP1 axis</article-title>
        <source>Oncol Lett</source>
        <volume>20</volume>
        <year>2020</year>
        <fpage>388</fpage>
        <pub-id pub-id-type="pmid">33193848</pub-id>
      </element-citation>
    </ref>
    <ref id="b0345">
      <label>69</label>
      <element-citation publication-type="journal" id="h0345">
        <person-group person-group-type="author">
          <name>
            <surname>Ramani</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Mato</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>S.C.</given-names>
          </name>
        </person-group>
        <article-title>Role of methionine adenosyltransferase genes in hepatocarcinogenesis</article-title>
        <source>Cancers (Basel)</source>
        <volume>3</volume>
        <year>2011</year>
        <fpage>1480</fpage>
        <lpage>1497</lpage>
        <pub-id pub-id-type="pmid">24212770</pub-id>
      </element-citation>
    </ref>
    <ref id="b0350">
      <label>70</label>
      <element-citation publication-type="journal" id="h0350">
        <person-group person-group-type="author">
          <name>
            <surname>Frau</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Feo</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Pascale</surname>
            <given-names>R.M.</given-names>
          </name>
        </person-group>
        <article-title>Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis</article-title>
        <source>J Hepatol</source>
        <volume>59</volume>
        <year>2013</year>
        <fpage>830</fpage>
        <lpage>841</lpage>
        <pub-id pub-id-type="pmid">23665184</pub-id>
      </element-citation>
    </ref>
    <ref id="b0355">
      <label>71</label>
      <element-citation publication-type="journal" id="h0355">
        <person-group person-group-type="author">
          <name>
            <surname>Xia</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors</article-title>
        <source>Front Oncol</source>
        <volume>10</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">572904</object-id>
      </element-citation>
    </ref>
    <ref id="b0360">
      <label>72</label>
      <element-citation publication-type="journal" id="h0360">
        <person-group person-group-type="author">
          <name>
            <surname>Suzuki</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Yokobori</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Gombodorj</surname>
            <given-names>N.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High stromal transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer</article-title>
        <source>J Surg Oncol</source>
        <volume>118</volume>
        <year>2018</year>
        <fpage>966</fpage>
        <lpage>974</lpage>
        <pub-id pub-id-type="pmid">30260476</pub-id>
      </element-citation>
    </ref>
    <ref id="b0365">
      <label>73</label>
      <element-citation publication-type="journal" id="h0365">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC</article-title>
        <source>Cell Death Dis</source>
        <volume>8</volume>
        <year>2017</year>
        <fpage>e3143</fpage>
        <pub-id pub-id-type="pmid">29072684</pub-id>
      </element-citation>
    </ref>
    <ref id="b0370">
      <label>74</label>
      <element-citation publication-type="journal" id="h0370">
        <person-group person-group-type="author">
          <name>
            <surname>Ramadori</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Ioris</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Villanyi</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>FKBP10 Regulates Protein Translation to Sustain Lung Cancer Growth</article-title>
        <source>Cell Rep</source>
        <volume>30</volume>
        <year>2020</year>
        <fpage>3851</fpage>
        <lpage>3863.e3856</lpage>
        <pub-id pub-id-type="pmid">32187554</pub-id>
      </element-citation>
    </ref>
    <ref id="b0375">
      <label>75</label>
      <element-citation publication-type="journal" id="h0375">
        <person-group person-group-type="author">
          <name>
            <surname>Desgrosellier</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Cheresh</surname>
            <given-names>D.A.</given-names>
          </name>
        </person-group>
        <article-title>Integrins in cancer: biological implications and therapeutic opportunities</article-title>
        <source>Nat Rev Cancer</source>
        <volume>10</volume>
        <year>2010</year>
        <fpage>9</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="pmid">20029421</pub-id>
      </element-citation>
    </ref>
    <ref id="b0380">
      <label>76</label>
      <element-citation publication-type="journal" id="h0380">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells</article-title>
        <source>Pathol Res Pract</source>
        <volume>215</volume>
        <year>2019</year>
        <object-id pub-id-type="publisher-id">152531</object-id>
      </element-citation>
    </ref>
    <ref id="b0385">
      <label>77</label>
      <element-citation publication-type="journal" id="h0385">
        <person-group person-group-type="author">
          <name>
            <surname>Han</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Hur</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1</article-title>
        <source>Gut</source>
        <volume>64</volume>
        <year>2015</year>
        <fpage>203</fpage>
        <lpage>214</lpage>
        <pub-id pub-id-type="pmid">24870620</pub-id>
      </element-citation>
    </ref>
    <ref id="b0390">
      <label>78</label>
      <element-citation publication-type="journal" id="h0390">
        <person-group person-group-type="author">
          <name>
            <surname>He</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Y.F.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a</article-title>
        <source>Sci Rep</source>
        <volume>6</volume>
        <year>2016</year>
        <fpage>21955</fpage>
        <pub-id pub-id-type="pmid">26903137</pub-id>
      </element-citation>
    </ref>
    <ref id="b0395">
      <label>79</label>
      <element-citation publication-type="journal" id="h0395">
        <person-group person-group-type="author">
          <name>
            <surname>Hamidi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ivaska</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Every step of the way: integrins in cancer progression and metastasis</article-title>
        <source>Nat Rev Cancer</source>
        <volume>18</volume>
        <year>2018</year>
        <fpage>533</fpage>
        <lpage>548</lpage>
        <pub-id pub-id-type="pmid">30002479</pub-id>
      </element-citation>
    </ref>
    <ref id="b0400">
      <label>80</label>
      <element-citation publication-type="journal" id="h0400">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Topologically inferring risk-active pathways toward precise cancer classification by directed random walk</article-title>
        <source>Bioinformatics</source>
        <volume>29</volume>
        <year>2013</year>
        <fpage>2169</fpage>
        <lpage>2177</lpage>
        <pub-id pub-id-type="pmid">23842813</pub-id>
      </element-citation>
    </ref>
    <ref id="b0405">
      <label>81</label>
      <element-citation publication-type="journal" id="h0405">
        <person-group person-group-type="author">
          <name>
            <surname>Goh</surname>
            <given-names>W.W.</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Protein complex-based analysis is resistant to the obfuscating consequences of batch effects –- a case study in clinical proteomics</article-title>
        <source>BMC Genomics</source>
        <volume>18</volume>
        <year>2017</year>
        <fpage>142</fpage>
        <pub-id pub-id-type="pmid">28361693</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0135" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0270">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0025"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p>
    <p id="p0275">
      <supplementary-material content-type="local-data" id="m0020">
        <caption>
          <title>Supplementary data 2</title>
        </caption>
        <media xlink:href="mmc2.docx"/>
      </supplementary-material>
    </p>
    <p id="p0280">
      <supplementary-material content-type="local-data" id="m0015">
        <caption>
          <title>Supplementary data 3</title>
        </caption>
        <media xlink:href="mmc3.xlsx"/>
      </supplementary-material>
    </p>
    <p id="p0285">
      <supplementary-material content-type="local-data" id="m0010">
        <caption>
          <title>Supplementary data 4</title>
        </caption>
        <media xlink:href="mmc4.xlsx"/>
      </supplementary-material>
    </p>
    <p id="p0290">
      <supplementary-material content-type="local-data" id="m0005">
        <caption>
          <title>Supplementary data 5</title>
        </caption>
        <media xlink:href="mmc5.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ak005">
    <title>Acknowledgement</title>
    <p id="p0260">The results shown here are part based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/tcga" id="ir030">https://www.cancer.gov/tcga</ext-link>.</p>
  </ack>
  <fn-group>
    <fn id="s0130" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0265">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2022.12.005" id="ir035">https://doi.org/10.1016/j.csbj.2022.12.005</ext-link>.</p>
    </fn>
  </fn-group>
</back>
